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introDuction to the thesis
“There is mere anger and grief and sad dejection of mind………those affected with 
melancholy are not every one of them affected according to one particular form 
but they are suspicious of poisoning or flee to the desert from misanthropy or turn 
superstitious or contract a hatred of life. The patients are dull or stern, dejected or 
unreasonably torpid……they also become peevish, dispirited and start up from a 
disturbed sleep.”
Arateus (AD 150)
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introDuction
Depression is a mental condition marked by ongoing feelings of sadness, despair, 
loss of energy, and difficulty dealing with normal daily life. The impact of depression 
on personal life can be devastating, as it can result in increased suffering, disability, 
loss of productivity, deliberate self-harm and it increases the risk of suicide.1,2 
 When used to describe a mood, depression refers to what may be feelings of 
sadness, despair, and discouragement, but depression is also used to describe the 
clinical diagnosis of major depressive disorder (MDD).2 According to the diagnostic 
and statistical manual of mental disorders (DSM-IV), a person suffers from MDD 
when depressed mood and/or loss of interest or pleasure are present two or more 
weeks. MDD is characterized by the presence of five or more of the following nine 
symptoms: depressed mood, diminished interest or pleasure, significant weight loss, 
insomnia or hypersomnia, psychomotor agitation or retardation, fatigue or loss of 
energy, feelings of worthlessness or excessive or inappropriate guilt, diminished abil-
ity to think or concentrate and recurrent thoughts of death.2
 Though MDD is the outcome of clinical interest, psychiatric research is focusing 
more and more on quantitative outcomes or endophenotypes.3 The endophenoty-
pes are also heritable and are probably determined more directly by genes. Another 
advantage of using quantitative outcomes is that criteria to distinguish affected from 
non-affected are often arbitrary.4 Studies of quantitative traits may be more powerful 
as the information on the total distribution of a trait is used. It should be noted how-
ever, that the relation between a quantitative trait such as symptoms of depression 
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and MDD is not unique. Symptoms of depression may be part of MDD but can also 
be indicative of normal grief, bipolar disorder, anxiety, substance abuse, dysphoria 
associated with other psychiatric disorders, and a variety of underlying medical ill-
nesses. Symptoms of depression, which may or may not be due to MDD, is used 
in a similar way as the phenotype of blood pressure. Blood pressure is studied as a 
determinant of multiple outcomes such as cardiovascular disease, stroke, dementia, 
or retinopathology; even though moderate increases in blood pressure often do not 
lead to clinical pathology. Studies of blood pressure have increased our knowledge 
about determinants of cardiovascular disease, likewise studies of symptoms of de-
pression may be relevant to our understanding of MDD. The work presented in this 
thesis focuses for a large part on symptoms of depression.
Epidemiology
Depression is the most frequently occurring psychiatric disease with a life-time 
incidence of around 25%.5 It is the leading cause of disability among individuals 
between 15 to 44 years of age, and is expected to become the second leading source 
of disability across all ages by 2020.6 The prevalence of symptoms of depression is 
higher in women, in singles, in individuals with severe alcohol use, those exposed 
to life stressors, negative early childhood experiences or those with a socioeco-
nomic disadvantage.7 It is clear that genetic factors play a significant role.8 Genetic 
epidemiological studies in families, twins and adopted individuals consistently show 
evidence for a genetic basis for depression.9 Heritability estimates, which denote 
the proportion of variability in a trait that can be attributed to additive genetic fac-
tors and shared early environmental factors, range from 0.17 to 0.78, depending on 
the population investigated.10 Further, several studies have shown that first-degree 
relatives of depressed patients have more than a three-fold increase in their risk of 
developing a depressive disorder compared with the general population.11 
Etiology
The etiology of depression is still far from being understood. It is known that it is 
multifactorial,7 and most likely a result of many genetic and environmental factors.10 
Serotoninergic and norepinephrine systems have been the main focus of research 
in depression.12 Serotonin is involved in the regulatory control of affect, aggression, 
sleep, and appetite, among others.13 Norepinephrine is involved in many functions 
that are profoundly disturbed in depression, including mood, arousal, appetite, 
reward, and drives.13 The hypothesis that these neurotransmitters are involved in 
the etiology of depression derive furthermore from pharmacological experience, as 
these neurotransmitters have been the basis of treatment for the last fifty years.12
introduction
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There are many other proposed mechanisms involved in depression.15 For example 
the dopamine system is especially important for pleasure, sex, and psychomo-
tor activity.15 The hypothalamic pituitary adrenal axis (HPA) controls reactions to 
stress and regulates mood, sexuality, and energy usage.16 The hypersecretion of 
corticotropin-releasing factor is thought to mediate sleep, appetite disturbances, 
reduced libido, and psychomotor changes.17 The renin angiotensin system directly 
modulates the HPA axis by stimulating corticotropin hormones.18,19 Cortisol inhibits 
neurogenesis leading to hippocampal volume loss that may mediate cognitive symp-
toms of depression.20 Cholinergic neurons, secreting acetylcholine at their dendritic 
terminals, are generally antagonistic to the function of serotonin and noradrenalin. 
Besides, there is increasing interest in second messenger systems, phosphorylation 
G proteins, signal transduction, deoxyribonucleic acid (DNA) transcription, and mes-
senger ribonucleic acid (RNA) translation.15 Genetic factors obviously play a role in 
these biochemical mechanisms,15 and major efforts are being made to identify the 
corresponding genes which are associated to depression. The identification of these 
genes may help to develop new classes of antidepressants with more selective action 
on specific neurotransmitter receptors. 
Genetic risk factors
During the past 30 years, many association studies of depression have been per-
formed, but so far most findings have been inconclusive. Meta-analyses for MDD 
have been conducted for five polymorphisms in four genes.21-26 These meta-analyses 
addressed the serotonin 5-HT-2A receptor (HTR2A), the methylenetetrahydrofolate 
reductase (MTHFR), the serotonin transporter (SLC6A4), and the tyrosine hydroxylase 
(TH) genes.21-26 The SLC6A4 44bp Ins/Del polymorphism is the most frequently stud-
ied to date and has been evaluated in three previous meta-analyses.21,24,26 The first 
meta-analysis, including only 275 patients, showed a statistically significant increased 
MDD risk for carriers of the S allele (OR, 1.23; CI, 1.01-1.42),24 but two subsequent 
larger meta-analyses were unable to confirm this finding.21,26 The MTHFR gene was 
also found to be significantly associated to depression (OR, 1.36; CI, 1.11-1.67).25 
 In recent years, genome-wide linkage screens have been conducted in families 
with multiple affected relatives.27-29 Despite differences in ascertainment, clinical 
assessment, phenotype definition and analysis technique, an increasing number 
of replications of findings have been observed. Seven regions were found to be 
replicated within 20 cM in at least two studies: 4q, 5q, 6q, 8p, 11q, 15q and 18q, 
although no region was confirmed in all studies.27-30 From these studies, the largest 
genome-wide linkage screen which was performed in 656 families, found genome 
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wide significant evidence for linkage to MDD in chromosome 15q25-q26, 17p12 and 
8p22-p21.3.28 Further fine mapping of the chromosome 15q25-q26 region suggested 
that several genes in this region increase susceptibility to MDD, but no single gene 
could be pinpointed.31 The authors refrained from speculating on possible candidate 
genes in the region. Another region implicated in MDD is the 12q22-23 region,32,33 
which overlaps with a region of interest of other psychiatric phenotypes such as 
bipolar disorder,33 and anxiety.34 Further research is warranted to identify genes in 
these regions that are associated with risk of depression. 
Aim of this study
Genetic epidemiological studies may enable us to unravel the etiology of depression 
through the identification of genes and therewith the proteins involved. The aim of 
this genetic epidemiological thesis is to study candidate genes that may play a role 
in the etiology of depression, and to obtain new insights about biological pathways 
that may be involved in the etiology of depression by identifying other disorders that 
share etiological pathways and hence may share the same underlying genes with 
depression. 
 Chapters 2 to 5 focus on the first aim. Chapter 2 describes a review of all genetic 
studies on major depressive disorder and meta-analyses for polymorphisms that 
had been investigated in at least three studies. In Chapter 3 the role of the DRD4 
48bp polymorphism in mood disorders is re-evaluated with a meta-analysis. This 
polymorphism has been consistently associated with attention deficit hyperactivity 
disorder , schizophrenia, and novelty-seeking.35-37 It has also been studied in rela-
tion to depression in past studies. However the findings were not consistent.38-41 In 
Chapter 4 the role of the angiotensin I converting enzyme gene (ACE I/D) in MDD 
is re-evaluated by conducting a case-control study and a meta-analysis. ACE is a 
component of the renin angiotensin system (RAS), a system that is assumed to be 
involved in depression. Evidence for this relationship comes from research showing 
that ACE inhibitors have antidepressant effects,42 and that the RAS modulates the 
HPA axis by stimulating corticotrophin hormones.19 In Chapter 5 the association 
between the AGT M235T polymorphism and symptoms of depression is examined 
in two independent populations.
 Chapters 6 to 8 focus on co-morbidity and the identification of biological path-
ways that may be involved in the etiology of depression. In Chapter 6 the role of 
shared genetic factors in the co-occurrence of symptoms of depression and socio-
economic status is investigated. In Chapter 7 the impact of shared genetic factors in 
the co-occurrence of symptoms of depression and cardiovascular risk factors such 
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as blood pressure, glucose levels and lipid parameters is examined. In Chapter 8 the 
relationship of shared genetic and environmental factors in the co-occurrence of 
body composition and symptoms of depression is studied. Finally, the results of the 
study are discussed in Chapter 9. 
References
1.  Lorant V, Deliege D, Eaton W, Robert A, Philippot P, Ansseau M. Socioeconomic inequalities in 
depression: a meta-analysis. Am J Epidemiol 2003;157:98-112.
2.  American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders-IV. 
Washington DC, 1994.
3.  Faraone SV, Santangelo, S. Research designs and methods in psychiatry. Amsterdam: Ed. Elsevier, 
1992.
4.  Carey G GI. Defining cases by genetic criteria. In What is a Case? London: Grant McIntyre, 1981.
5.  Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology 
of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). 
JAMA 2003;289:3095-105.
6.  Murray CJ, López AD. Evidence-based health policy-lessons from the Global Burden of Disease 
Study. Science 1996; 274: 740–743
7.  Blazer DG, 2nd, Hybels CF. Origins of depression in later life. Psychol Med 2005;35:1241-52.
8.  Kendler KS. Major depression and the environment: a psychiatric genetic perspective. Pharma-
copsychiatry 1998;31:5-9.
9.  Craddock N, Forty L. Genetics of affective (mood) disorders. Eur J Hum Genet 2006;14:660-8.
10.  Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-
analysis. Am J Psychiatry 2000;157:1552-62.
11.  Weissman MM, Gershon ES, Kidd KK, Prusoff BA, Leckman JF, Dibble E, et al. Psychiatric disor-
ders in the relatives of probands with affective disorders. The Yale University – National Institute of 
Mental Health Collaborative Study. Arch Gen Psychiatry 1984;41:13-21.
12.  Hardman JG, Limbird LE, Molinoff PB, Ruddon RW. Goodman & Gilman, The Pharmacological 
Basis of Therapeutics. New York: A. McGraw-Hill, 1996.
13.  Maes M MH. The serotonin hypothesis of major depression. In Psychopharmacology: The Fourth 
Generation of Progress. New York: Raven Press, 1995.
14.  Schatzberg AF SJ. Recent studies on norepinephrine systems in mood disorders. In Psychopharma-
cology: The Fourth Generation of Progress. New York: Raven Press, 1995.
15.  Kaplan HI, Sadock BJ. Sypnosis of Psychiatry 8th Edition. Baltimore, USA.: Williams & Wilkins, 
2005.
16. Engelmann M, Landgraf R, Wotjak CT. The hypothalamic-neurohypophysial system regulates the 
hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Front Neuroendocrinol 
2004;25:132-49.
17.  Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in 
depression and anxiety disorders. J Endocrinol 1999;160:1-12.
18.  Jezova D, Ochedalski T, Kiss A, Aguilera G. Brain angiotensin II modulates sympathoadrenal and 
hypothalamic pituitary adrenocortical activation during stress. J Neuroendocrinol 1998;10: 67-72.
19.  Plotsky PM, Owens MJ, Nemeroff CB. Psychoneuroendocrinology of depression. Hypothalamic-
pituitary-adrenal axis. Psychiatr Clin North Am 1998;21:293-307.
20.  Sapolsky RM. Depression, antidepressants, and the shrinking hippocampus. Proc Natl Acad Sci U 
S A 2001;98:12320-2.
21.  Lasky-Su JA, Faraone SV, Glatt SJ, Tsuang MT. Meta-analysis of the association between two 
polymorphisms in the serotonin transporter gene and affective disorders. Am J Med Genet B Neu-
ropsychiatr Genet 2005;133:110-5.
chaPter 1
16
22.  Zintzaras E. C677T and A1298C methylenetetrahydrofolate reductase gene polymorphisms in 
schizophrenia, bipolar disorder and depression: a meta-analysis of genetic association studies. 
Psychiatr Genet 2006;16:105-15.
23.  Furlong RA, Rubinsztein JS, Ho L, Walsh C, Coleman TA, Muir WJ, et al. Analysis and metaanaly-
sis of two polymorphisms within the tyrosine hydroxylase gene in bipolar and unipolar affective 
disorders. Am J Med Genet 1999;88:88-94.
24.  Furlong RA, Ho L, Walsh C, Rubinsztein JS, Jain S, Paykel ES, et al. Analysis and meta-analysis 
of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. Am J 
Med Genet 1998;81:58-63.
25.  Lewis SJ, Lawlor DA, Davey Smith G, Araya R, Timpson N, Day IN, et al. The thermolabile variant 
of MTHFR is associated with depression in the British Women’s Heart and Health Study and a 
meta-analysis. Mol Psychiatry 2006;11:352-60.
26.  Anguelova M, Benkelfat C, Turecki G. A systematic review of association studies investigating 
genes coding for serotonin receptors and the serotonin transporter: I. Affective disorders. Mol 
Psychiatry 2003;8:574-91.
27.  Zubenko GS, Maher B, Hughes HB, 3rd, Zubenko WN, Stiffler JS, Kaplan BB, et al. Genome-
wide linkage survey for genetic loci that influence the development of depressive disorders in 
families with recurrent, early-onset, major depression. Am J Med Genet B Neuropsychiatr Genet 
2003;123:1-18.
28.  Holmans P, Weissman MM, Zubenko GS, Scheftner WA, Crowe RR, Depaulo JR, Jr., et al. Genet-
ics of recurrent early-onset major depression (GenRED): final genome scan report. Am J Psychiatry 
2007;164:248-58.
29.  Camp NJ, Lowry MR, Richards RL, Plenk AM, Carter C, Hensel CH, et al. Genome-wide linkage 
analyses of extended Utah pedigrees identifies loci that influence recurrent, early-onset major 
depression and anxiety disorders. Am J Med Genet B Neuropsychiatr Genet 2005;135:85-93.
30.  Camp NJ, Cannon-Albright LA. Dissecting the genetic etiology of major depressive disorder using 
linkage analysis. Trends Mol Med 2005;11:138-44.
31.  Levinson DF, Evgrafov OV, Knowles JA, Potash JB, Weissman MM, Scheftner WA, et al. Genetics 
of recurrent early-onset major depression (GenRED): significant linkage on chromosome 15q-
5-q26 after fine mapping with single nucleotide polymorphism markers. Am J Psychiatry 2007;164: 
259-64.
32.  Abkevich V, Camp NJ, Hensel CH, Neff CD, Russell DL, Hughes DC, et al. Predisposition locus 
for major depression at chromosome 12q22-12q23.2. Am J Hum Genet 2003;73:1271-81.
33.  McGuffin P, Knight J, Breen G, Brewster S, Boyd PR, Craddock N, et al. Whole genome linkage 
scan of recurrent depressive disorder from the depression network study. Hum Mol Genet 2005;14: 
3337-45.
34.  Fullerton J, Cubin M, Tiwari H, Wang C, Bomhra A, Davidson S, et al. Linkage analysis of 
extremely discordant and concordant sibling pairs identifies quantitative-trait loci that influence 
variation in the human personality trait neuroticism. Am J Hum Genet 2003;72:879-90.
35.  Schinka JA, Letsch EA, Crawford FC. DRD4 and novelty seeking: results of meta-analyses. Am J 
Med Genet 2002;114:643-8.
36.  Faraone SV, Biederman J, Weiffenbach B, Keith T, Chu MP, Weaver A, et al. Dopamine D4 gene 
7-repeat allele and attention deficit hyperactivity disorder. Am J Psychiatry 1999;156:768-70.
37.  Glatt SJ, Faraone SV, Tsuang MT. Schizophrenia is not associated with DRD4 48-base-pair-repeat 
length or individual alleles: results of a meta-analysis. Biol Psychiatry 2003;54:629-35.
38.  Manki H, Kanba S, Muramatsu T, Higuchi S, Suzuki E, Matsushita S, et al. Dopamine D2, D3 and 
D4 receptor and transporter gene polymorphisms and mood disorders. J Affect Disord 1996;40: 
7-13.
39.  Frisch A, Postilnick D, Rockah R, Michaelovsky E, Postilnick S, Birman E, et al. Association of 
unipolar major depressive disorder with genes of the serotonergic and dopaminergic pathways. 
Mol Psychiatry 1999;4:389-92.
introduction
17
40.  Oruc L, Verheyen GR, Furac I, Jakovljevic M, Ivezic S, Raeymaekers P, et al. Analysis of the tyro-
sine hydroxylase and dopamine D4 receptor genes in a Croatian sample of bipolar I and unipolar 
patients. Am J Med Genet 1997;74:176-8.
41.  Serretti A, Macciardi F, Cusin C, Lattuada E, Lilli R, Smeraldi E. Dopamine receptor D4 gene is 
associated with delusional symptomatology in mood disorders. Psychiatry Res 1998;80:129-36.
42.  Vuckovic A, Cohen BM, Zubenko GS. The use of captopril in treatment-resistant depression: an 
open trial. J Clin Psychopharmacol 1991;11:395-6.

19
2
meta-analyses of Genetic stuDies 
on major Depressive DisorDer 
Abstract 
The genetic basis of major depressive disorder (MDD) has been investigated exten-
sively, but the identification of MDD genes has been hampered by conflicting results 
from underpowered studies. We review all MDD case-control genetic association 
studies published before June 2007 and perform meta-analyses for polymorphisms 
that had been investigated in at least three studies. The study selection and data 
extraction were performed in duplicate by two independent investigators. The 183 
papers that met our criteria studied 393 polymorphisms in 102 genes. Twenty-two 
polymorphisms (6%) were investigated in at least three studies. Seven polymor-
phisms had been evaluated in previous meta-analyses, of which for five new were 
data available. Hence, we performed meta-analyses for 20 polymorphisms in 18 
genes. Pooled odds ratios (ORs) with 95% confidence intervals (CI) were calculated. 
Statistically significant associations were found for the APOE ε2 (OR, 0.51), GNB3 
825T (OR, 1.38), MTHFR 677T (OR, 1.20), SLC6A4 44bp Ins/Del S (OR, 1.11) alleles 
and the SLC6A3 40bpVNTR 9/10 genotype (OR, 2.06). To date, there is statistically 
significant evidence for six MDD susceptibility genes (APOE, DRD4, GNB3, MTHFR, 
SLC6A3 and SLC6A4). 
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Introduction 
Depression is the leading cause of disability for individuals of 15 to 44 years of age 
and is expected to become the second cause of disability worldwide for individuals 
of all ages by the year 2020.1 MDD is caused by a complex interaction of a large 
number of genetic and non-genetic factors, each with a relatively small contribution 
to the disorder.2 The total contribution of genetic factors in the origin of disease, 
the heritability, is estimated at 37%.3 First-degree relatives of MDD patients have a 
two- to threefold increased risk of MDD compared to the general population.4 
 Since the first case-control study on the relationship between polymorphisms 
and depression in 1978,5 many genetic association studies have been conducted. 
Nevertheless, this accumulation of research has not resulted in the identification 
of many MDD susceptibility genes, because the findings of the association studies 
have often been inconsistent.6 A first explanation for these inconsistencies concern 
methodological differences between the studies, such as differences in study design, 
study population and MDD diagnostic criteria, which hamper the comparability of 
the studies. A second explanation is that many studies had small sample sizes and 
therefore insufficient statistical power to demonstrate statistically significant effects 
of these low-risk susceptibility genes.7 The impact of latter problem can be reduced 
by pooling single studies in meta-analyses.8 
 To date, meta-analyses for MDD have been conducted for seven polymorphisms 
in six genes (Table 1). These meta-analyses included the genes encoding for angio-
tensin I-converting enzyme (ACE), dopamine receptor D4 (DRD4), serotonin 5-HT-2A 
receptor (HTR2A), methylenetetrahydrofolate reductase (MTHFR), serotonin trans-
porter (SLC6A4) and tyrosine hydroxylase (TH).9-16 The DRD4 gene was significantly 
associated to MDD (odds ratio (OR), 1.73; 95% confidence interval (CI), 1.29-2.32),12 
and the MTHFR was significantly associated to depression (OR, 1.36; CI, 1.11-1.67).15 
SLC6A4 44bp Ins/Del is the most frequently studied polymorphism to date and has 
been evaluated in three previous meta-analyses.9,14,16 The first meta-analysis, in-
cluding only 275 patients, showed a statistically significant increased MDD risk for 
carriers of the S allele (OR, 1.23),13 but two subsequent larger meta-analyses were 
unable to confirm this finding.9,16 
 Many other genes have been studied in relation to MDD. Our aim is to review all 
case-control studies on the association between genetic polymorphisms and MDD 
and perform meta-analyses for polymorphisms that had been investigated in at least 
three studies.
Meta-analyses of genetic studies on Major dePressive disorder
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Materials and Methods
Data Sources
We searched PubMed for genetic case-control association studies on MDD pub-
lished before June 2007. The search strategy was based on the keywords unipolar 
depression, major depression, depressive disorder or affective disorder in combina-
tion with chromosome, gene, allele or polymorphism. A second search was carried 
out using the name of the genes identified in the first search in combination with a 
broader keyword search: unipolar, depression, depressive or affective. In addition, 
we searched the PubMed, HuGeNet, ISI Web of Science databases, the Genetic 
Association Database, and the reference lists of the retrieved articles.
Study Selection 
Genetic association studies were selected if they had applied a case-control design 
and compared adults diagnosed with standard diagnostic criteria for MDD. Studies 
were excluded if (1) cases were selected by questionnaires assessing symptoms of 
depression, (2) the study population included bipolar patients, (3) the distribution of 
genotypes in the control population was not in Hardy-Weinberg Equilibrium, or (4) if 
the data were re-used in a larger study on the same polymorphism. Study selection 
and data extraction were performed in duplicate by two independent investiga-
tors (S.L.L. and A.G.Z.) and discrepancies were discussed with a third investigator 
(A.C.J.W.J).
Data Synthesis 
Meta-analyses were performed for polymorphisms that had been investigated in 
at least three studies. Published meta-analyses were updated when new studies 
were available. ORs were summarized using both random effects and fixed effects 
meta-analyses with 95% CIs as outlined by DerSimonian and Laird.17 The degree of 
heterogeneity between the study results was assessed with the I2 statistics.18 Forest 
plots were obtained for meta-analyses with statistically significant results, presenting 
random effect meta-analyses if there was evidence of heterogeneity (I2>50),19 and 
fixed effects meta-analyses if there is no heterogeneity. Sources of heterogeneity 
were explored in sensitivity analyses by removing one study at a time and calculating 
pooled ORs on the remaining studies. Sensitivity analysis also examines the extent 
to which pooled ORs were determined by significant effects of the first published 
study.7 Publication bias was evaluated by visual inspection of the funnel plots.20 
Cochrane Review Manager Version 4.2 was used for all statistical analyses. P values 
lower than 0.05 (two-tailed) were considered statistically significant. 
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Results 
Of the 215 articles that met our inclusion criteria, 32 were excluded. Five studies 
selected cases by questionnaires assessing symptoms of depression,21-25 nine studied 
MDD and bipolar depression without reporting separate genotype frequencies for 
the subtypes,26-34 eight had genotype frequencies in controls that were not in Hardy-
Weinberg Equilibrium,35-42 and ten reported data that had later been re-used in a 
larger study for the same polymorphism.43-52 The remaining 183 articles studied 393 
different polymorphisms in 102 genes (Figure 1). Of the 393 polymorphisms, 371 
were investigated in one or two studies (Table 2). Only 22 (6%) polymorphisms in 20 
(19%) genes were investigated in more than 3 studies. 
Retrieved
215 articles
Excluded
32 articles
Included
183 articles
393 polymorphisms
102 genes
Less than 3 studies
371 polymorphisms
97 genes*
3 or more studies
22 polymorphisms
20 genes*
New meta-analyses
15 polymorphisms
Previous meta-analyses
New data
5 polymorphisms
Previous meta-analyses
No new data
2 polymorphisms
Meta-analyses
20 polymorphisms
18 genes
Figure 1 Selection of studies for the meta-analyses
* The number of genes does not add up to 102, because 8 genes were investigated for multiple polymor-
phisms of which some were addressed in more than three studies. 
Of the 22 polymorphisms, 7 had been reviewed in previous meta-analyses, of which 
for 5 polymorphisms (ACE I/D, HTR2A T102C, MTHFR C677T, SLC6A4 VNTR and 
SLC6A4 44bp Ins/Del) new data was available. Hence, we performed meta-analyses 
for 20 polymorphisms in 18 genes (Table 3). Five polymorphisms showed statisti-
cally significant association to MDD: apolipoprotein E (APOE), guanine nucleotide-
binding protein (GNB3) 825T, MTHFR 677T, dopamine transporter (SLC6A3) 40bp 
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VNTR, and the SLC6A4 44bp Ins/Del (Figure 2). Figure 3 shows the funnel plots for 
the statistically significant meta-analysis. 
Figure 2 Forest plots for statistically significant meta-analyses 
 
APOE
The APOE ε2 allele was examined in 7 studies including a total of 827 cases and 
1,616 controls.53-59 One study found a very strong protective effect for the ε2 allele 
(OR, 0.06; CI, 0.02-0.21),57 while the others showed moderate protective effects (OR 
varying from 0.45 to 1; Figure 2). The pooled OR of the ε2 allele compared to the ε3 
allele was 0.51 (CI, 0.27-0.97). The per allele meta-analysis of studies in Caucasian 
populations also showed a statistically significant pooled OR (0.72; CI, 0.51-1.00) 
with no evidence for between-study heterogeneity.54-58 There were not enough 
studies to perform a meta-analysis of only studies from Asian origin. The pooled OR 
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of the ε2 allele was not statistically significant when the first published study was 
removed from the analysis (OR, 0.51; CI, 0.25-1.05).57 The funnel plot show that the 
three smaller studies had lower ORs than the larger studies (Figure 3), but that there 
was no convincing evidence for publication bias.
0.0
0.2
0.4
0.6
0.8
0.1 0.2 0.5 1 2 5 10
APOE E2/E3
SE(log OR)
0.00
0.04
0.08
0.12
0.16
0.1 0.2 0.5 1 2 5 10
GNB3 C825T
SE(log OR)
OR OR
0.0
0.1
0.2
0.3
0.4
0.1 0.2 0.5 1 2 5 10
MTHFR C677T
SE(log OR)
OR
0.0
0.2
0.4
0.6
0.8
0.1 0.2 0.5 1 2 5 10
SLC6A3 9/10
SE(log OR)
0.0
0.1
0.2
0.3
0.4
0.1 0.2 0.5 1 2 5 10
SLC6A4 44bp S/L
SE(log OR)
OR OR
Figure 3 Funnel plots for statistically significant meta-analyses
Each dot represents one paper. Se(log OR) = standard error of the log Odds Ratio.
GNB3 
The association between the GNB3 C825T polymorphism and MDD was investi-
gated in 3 studies with a total of 375 cases and 492 controls.45,60,61 All ORs in the 
individual studies were greater than 1. The per allele meta-analysis, testing for a trend 
by the number of T alleles, showed a significant effect of the T allele (OR, 1.38; CI, 
1.13-1.69; Figure 2). 
MTHFR
Six studies investigated the MTHFR C677T polymorphism in a total of 875 cases and 
3,859 controls. 15,62-66 Five studies showed an increased MDD risk for homozygous 
carriers of the T allele, but this association was only statistically significant in 1 
study (Figure 2).62 The combined OR was 1.20 (CI, 1.07-1.34) for the T allele, 1.38 
(CI, 1.08-1.76) for homozygous carriers, and 1.22 (CI, 1.03-1.44) for heterozygous 
carriers. These associations were still statistically significant when the first published 
study was removed (ORTvsC, 1.18; CI, 1.05-1.32, ORTCvsCC, 1.22; CI, 1.03-1.44, ORT-
TvsCC, 1.31; CI, 1.02-1.69).
62
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SLC6A3
The SLC6A3 40bp VNTR polymorphism was investigated in 3 studies including a 
total of 151 cases and 272 controls.67,68 Each study showed an increased MDD risk 
for carriers of the 9/10 genotype compared to the 10/10 genotype, but only 1 study 
was statistically significant.68 The pooled OR for the 9/10 genotype compared to the 
10/10 genotype was 2.06 (CI, 1.25-3.40). 
SLC6A4
Twenty-four studies investigated SLC6A4 44bp Ins/Del short/long (S/L) polymor-
phism including a total of 3,752 cases and 5,707 controls. 14,42,52,69-77 Twenty of the 
individual studies reported an OR higher than 1 for the S allele versus the L allele, 
but only in 3 studies was this association statistically significant (Figure 2).78-80 The 
pooled OR for the S allele was 1.11 (CI, 1.04-1.19) and the pooled OR for homozygous 
carriers was 1.39 (CI, 1.20-1.61). When the first published study was removed, these 
ORs remained statistically significant (ORSvsL, 1.11; CI, 1.01-1.22, ORSSvsLL, 1.37; CI, 
1.16-1.61).81 The funnel plot shows asymmetry as 17 out of the 24 studies show a 
higher OR than the pooled estimate, but there was no evidence for publication bias 
towards studies with higher OR (Figure 3).
Other Genes
The remaining meta-analyses were not significant, their odds ratios ranged from 0.74 
to 0.99 for protective effects and from 1.09 to 1.63 for risk alleles/genotypes. Figure 
4 shows the ORs in relation to the total number of cases and controls that were 
included in the meta-analyses. Fifteen out of 20 meta-analyses included less than 
3,000 subjects in total, of which 12 had less than 1,000 cases. For example, the 
meta-analysis of DRD3 Ser9Gly polymorphism included 541 cases and 606 controls. 
The OR of the homozygous carriers was 1.71 and was not significant. In contrast, the 
meta-analysis of the SLC6A4 44bp Ins/Del polymorphism totaled more than 9,000 
persons and had a statistically significant OR of 1.11 for the S allele.
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Table 3 Meta-analyses of genetic association studies on major depressive disorder
Heterozygotes Homozygotes Per allele
Gene Variant Studies Analysis Comparison OR (95% CI) I2 Comparison OR (95% CI) I2 Studies Comparison OR (95% CI) I2 References
ACE Ins/Del 8 Fixed ID vs II 0.94 (0.78-1.13) 27 DD vs II 1.15 (0.94-1.42) 26 8 D vs I 1.08 (0.97-1.20) 0 11,100,179-183
-Intron 16 Random 0.90 (0.71-1.13) 1.11 (0.85-1.45) 1.05 (0.91-1.21)
APOE ε2/ε3/ε4 5 Fixed ε2/ε3 vs ε3/ε3 0.42 (0.28-0.62)*** 72* ε2/ε2 vs ε3/ε3 NA 7 ε2 vs ε3 0.51 (0.39-0.68)*** 74***53-59
Random 0.41 (0.15-1.07) NA 0.51 (0.27-0.97)*
5 Fixed ε3/ε4 vs ε3/ε3 1.02 (0.78-1.35) 0 ε4/ε4 vs ε3/ε3 1.02 (0.44-2.37) 32 7 ε4 vs ε3 0.93 (0.76-1.14) 4 53-59,140
Random 1.02 (0.78-1.35) 0.91 (0.25-3.33) 0.93 (0.75-1.15)
BDNF Val66Met 8 Fixed Val/Met vs Val/Val 0.98 (0.89-1.09) 0 Met/Met vs Val/Val 1.05 (0.84-1.32) 53* 8 Met vs Val 1.01 (0.93-1.09) 55* 141,184-188‡
Random 0.98 (0.89-1.09) 1.09 (0.72-1.65) 1.04 (0.90-1.21)
COMT Val158Met 6 Fixed Val/Met vs Val/Val 1.14 (0.86-1.52) 29 Met/Met vs Val/Val 0.95 (0.67-1.33) 12 8 Met vs Val 0.98 (0.86-1.13) 43 68,127,128,189-192
Random 1.13 (0.81-1.59) 0.95 (0.65-1.39) 1.00 (0.83-1.21)
DRD3 Ser9Gly 4 Fixed Ser/Gly vs Ser/Ser 0.92 (0.67-1.26) 33 Gly/Gly vs Ser/Ser 1.31 (0.80-2.14) 72* 4 Gly vs Ser 1.06 (0.85-1.34) 73** 67,94,127,193‡
Random 0.96 (0.64-1.45) 1.71 (0.57-5.13) 1.19 (0.74-1.89)
GABRA3 CA repeat 6 Fixed */1 vs 1/1 0.74 (0.49-1.12) 46 */* vs 1/1 0.92 (0.40-2.11) 10 6 Others vs 1 0.91 (0.68-1.20) 49 194,195
-Intron 8 Random 0.63 (0.32-1.25) 0.97 (0.36-2.62) 0.88 (0.55-1.40)
GNB3 C825T 3 Fixed CT vs CC 1.25 (0.91-1.72) 50 TT vs CC 2.13 (1.39-3.28)** 67* 4 T vs C 1.38 (1.13-1.69)** 41 45,60, 61
Random 1.30 (0.81-2.09) 2.09 (0.97-4.51) 1.36 (1.04-1.77)*
HTR1A C-1019G 4 Fixed CG vs CC 0.98 (0.72-1.33) 18 GG vs CC 1.33 (0.95-1.87) 79** 4 G vs C 1.16 (0.98-1.38) 77** 94,196-198‡
Random 0.98 (0.69-1.38) 1.63 (0.72-3.70) 1.25 (0.85-1.84)
HTR1B G861C 3 Fixed GC vs GG 0.99 (0.74-1.33) 42 CC vs GG 0.81 (0.46-1.41) 25 3 C vs G 0.96 (0.77-1.20) 48 94, 199, 200‡
Random 0.98 (0.66-1.44) 0.79 (0.41-1.53) 0.94 (0.69-1.29)
HTR2A A-1438G 4 Fixed AG vs AA 1.23 (0.88-1.73) 62* GG vs AA 1.06 (0.73-1.55) 75** 4 G vs A 1.01 (0.85-1.21) 73** 94, 201-203‡
Random 1.15 (0.65-2.03) 0.98 (0.45-2.14) 0.96 (0.67-1.36)
T102C 8 Fixed TC vs TT 1.00 (0.79-1.27) 0 CC vs TT 0.92 (0.71-1.21) 17 8 C vs T 0.96 (0.84-1.09) 26 68, 94, 204-208‡
Random 1.00 (0.79-1.27) 0.92 (0.68-1.25) 0.96 (0.82-1.12)
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Table 3 Meta-analyses of genetic association studies on major depressive disorder
Heterozygotes Homozygotes Per allele
Gene Variant Studies Analysis Comparison OR (95% CI) I2 Comparison OR (95% CI) I2 Studies Comparison OR (95% CI) I2 References
ACE Ins/Del 8 Fixed ID vs II 0.94 (0.78-1.13) 27 DD vs II 1.15 (0.94-1.42) 26 8 D vs I 1.08 (0.97-1.20) 0 11,100,179-183
-Intron 16 Random 0.90 (0.71-1.13) 1.11 (0.85-1.45) 1.05 (0.91-1.21)
APOE ε2/ε3/ε4 5 Fixed ε2/ε3 vs ε3/ε3 0.42 (0.28-0.62)*** 72* ε2/ε2 vs ε3/ε3 NA 7 ε2 vs ε3 0.51 (0.39-0.68)*** 74***53-59
Random 0.41 (0.15-1.07) NA 0.51 (0.27-0.97)*
5 Fixed ε3/ε4 vs ε3/ε3 1.02 (0.78-1.35) 0 ε4/ε4 vs ε3/ε3 1.02 (0.44-2.37) 32 7 ε4 vs ε3 0.93 (0.76-1.14) 4 53-59,140
Random 1.02 (0.78-1.35) 0.91 (0.25-3.33) 0.93 (0.75-1.15)
BDNF Val66Met 8 Fixed Val/Met vs Val/Val 0.98 (0.89-1.09) 0 Met/Met vs Val/Val 1.05 (0.84-1.32) 53* 8 Met vs Val 1.01 (0.93-1.09) 55* 141,184-188‡
Random 0.98 (0.89-1.09) 1.09 (0.72-1.65) 1.04 (0.90-1.21)
COMT Val158Met 6 Fixed Val/Met vs Val/Val 1.14 (0.86-1.52) 29 Met/Met vs Val/Val 0.95 (0.67-1.33) 12 8 Met vs Val 0.98 (0.86-1.13) 43 68,127,128,189-192
Random 1.13 (0.81-1.59) 0.95 (0.65-1.39) 1.00 (0.83-1.21)
DRD3 Ser9Gly 4 Fixed Ser/Gly vs Ser/Ser 0.92 (0.67-1.26) 33 Gly/Gly vs Ser/Ser 1.31 (0.80-2.14) 72* 4 Gly vs Ser 1.06 (0.85-1.34) 73** 67,94,127,193‡
Random 0.96 (0.64-1.45) 1.71 (0.57-5.13) 1.19 (0.74-1.89)
GABRA3 CA repeat 6 Fixed */1 vs 1/1 0.74 (0.49-1.12) 46 */* vs 1/1 0.92 (0.40-2.11) 10 6 Others vs 1 0.91 (0.68-1.20) 49 194,195
-Intron 8 Random 0.63 (0.32-1.25) 0.97 (0.36-2.62) 0.88 (0.55-1.40)
GNB3 C825T 3 Fixed CT vs CC 1.25 (0.91-1.72) 50 TT vs CC 2.13 (1.39-3.28)** 67* 4 T vs C 1.38 (1.13-1.69)** 41 45,60, 61
Random 1.30 (0.81-2.09) 2.09 (0.97-4.51) 1.36 (1.04-1.77)*
HTR1A C-1019G 4 Fixed CG vs CC 0.98 (0.72-1.33) 18 GG vs CC 1.33 (0.95-1.87) 79** 4 G vs C 1.16 (0.98-1.38) 77** 94,196-198‡
Random 0.98 (0.69-1.38) 1.63 (0.72-3.70) 1.25 (0.85-1.84)
HTR1B G861C 3 Fixed GC vs GG 0.99 (0.74-1.33) 42 CC vs GG 0.81 (0.46-1.41) 25 3 C vs G 0.96 (0.77-1.20) 48 94, 199, 200‡
Random 0.98 (0.66-1.44) 0.79 (0.41-1.53) 0.94 (0.69-1.29)
HTR2A A-1438G 4 Fixed AG vs AA 1.23 (0.88-1.73) 62* GG vs AA 1.06 (0.73-1.55) 75** 4 G vs A 1.01 (0.85-1.21) 73** 94, 201-203‡
Random 1.15 (0.65-2.03) 0.98 (0.45-2.14) 0.96 (0.67-1.36)
T102C 8 Fixed TC vs TT 1.00 (0.79-1.27) 0 CC vs TT 0.92 (0.71-1.21) 17 8 C vs T 0.96 (0.84-1.09) 26 68, 94, 204-208‡
Random 1.00 (0.79-1.27) 0.92 (0.68-1.25) 0.96 (0.82-1.12)
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Heterozygotes Homozygotes Per allele
Gene Variant Studies Analysis Comparison OR (95% CI) I2 Comparison OR (95% CI) I2 Studies Comparison OR (95% CI) I2 References
HTR2C Cys23Ser 2 Fixed Cys/Ser vs Cys/Cys NA Ser/Ser vs Cys/Cys NA 13 Ser vs Cys 1.03 (0.85-1.25 50* 68, 94, 209 ‡
Random NA NA 0.96 (0.73-1.28)
MAOA VNTR† 4 Fixed 12 vs 22 1.34 (0.95-1.89) 17 11 vs 22 0.71 (0.49-1.02) 0 6 1 vs 2 0.86 (0.74-1.01) 65* 210-215
-Promotor Random 1.29 (0.87-1.91) 0.71 (0.49-1.03) 0.86 (0.65-1.13)
MTHFR C677T 6 Fixed CT vs CC 1.22 (1.03-1.44)* 26 TT vs CC 1.38 (1.08-1.76)* 0 6 T vs C 1.20 (1.07-1.34)** 0 15,62-66
Random 1.23 (0.95-1.58) 1.38 (1.08-1.77)* 1.20 (1.07-1.34)**
SLC6A2 T-182C 3 Fixed TC vs TT 1.21 (0.91-1.61) 52 CC vs TT 0.72 (0.45-1.14) 64 3 C vs T 0.97 (0.80-1.18) 68* 125,216,217
Random 1.23 (0.81-1.85) 0.75 (0.33-1.67) 0.99 (0.70-1.40)
SLC6A3 40bp VNTR 3 Fixed 9/10 vs 10/10 2.06 (1.25-3.40)** 0 9/9 vs 10/10 1.46 (0.67-3.16) 0 3 9 vs 10 1.38 (0.98-1.94) 0 67, 68
(DAT1) -31-UTR region Random 2.05 (1.24-3.40)** 1.47 (0.67-3.19) 1.38 (0.98-1.94)
SLC6A4 44bp Ins/Del 22 Fixed LS vs LL 1.05 (0.94-1.18) 0 SS vs LL 1.39 (1.20-1.61)** 0 24 S vs L 1.11 (1.04-1.19)** 30 (32,45,61-70,72-80)‡
(SERT) -Promotor Random 1.05 (0.93-1.18) 1.39 (1.20-1.61)** 1.12 (1.03-1.22)**
VNTR 8 Fixed 9/12 vs 12/12 1.25 (0.61-2.55) 0 9/9 vs 12/12 NA 0 11 9 vs 12 1.33 (0.78-2.27)* 0 14,42,52,69-77
Intron 2 Random 1.22 (0.58-2.56) NA 1.24 (0.69-2.23)
8 Fixed 10/12 vs 12/12 0.94 (0.74-1.20) 24 10/10 vs 12/12 1.17 (0.82-1.68) 11 10 vs 12 1.02 (0.89-1.17) 0 (14,35,190-199)
Random 0.98 (0.73-1.32) 1.18 (0.82-1.70) 1.04 (0.91-1.20)
TPH1 A218C 9 Fixed AC vs AA 1.10 (0.91-1.34) 49 CC vs AA 0.88 (0.71-1.09) 35 9 C vs A 0.94 (0.85-1.04) 6 68,94,146,151,218-221‡
Random 1.14 (0.85-1.52) 0.86 (0.65-1.14) 0.94 (0.84-1.05)
I2 = Heterogeneity, in percentage; OR = odds ratio, CI = confidence interval NA = Not applicable, if data were 
available on less than three studies.
*p≤0.05, **p≤0.01, ***p≤0.001
† Allele 1, 30 bp-repeat sequence present in 3 copies associated with lower transcription activity; allele 2, 
present in 3.5, 4 and 5 copies of 30 bp-repeat sequence associated with higher transcription activity.
Note: It was not possible to perform a meta-analyses for the TPH2 G1463A polymorphism, because 4 out of 5 
papers did not find the 1463A allele in cases nor in controls.
‡ References 17 to 19 did not present complete information on genotype frequencies. Authors were contacted 
and all provided genotype data. 
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Heterozygotes Homozygotes Per allele
Gene Variant Studies Analysis Comparison OR (95% CI) I2 Comparison OR (95% CI) I2 Studies Comparison OR (95% CI) I2 References
HTR2C Cys23Ser 2 Fixed Cys/Ser vs Cys/Cys NA Ser/Ser vs Cys/Cys NA 13 Ser vs Cys 1.03 (0.85-1.25 50* 68, 94, 209 ‡
Random NA NA 0.96 (0.73-1.28)
MAOA VNTR† 4 Fixed 12 vs 22 1.34 (0.95-1.89) 17 11 vs 22 0.71 (0.49-1.02) 0 6 1 vs 2 0.86 (0.74-1.01) 65* 210-215
-Promotor Random 1.29 (0.87-1.91) 0.71 (0.49-1.03) 0.86 (0.65-1.13)
MTHFR C677T 6 Fixed CT vs CC 1.22 (1.03-1.44)* 26 TT vs CC 1.38 (1.08-1.76)* 0 6 T vs C 1.20 (1.07-1.34)** 0 15,62-66
Random 1.23 (0.95-1.58) 1.38 (1.08-1.77)* 1.20 (1.07-1.34)**
SLC6A2 T-182C 3 Fixed TC vs TT 1.21 (0.91-1.61) 52 CC vs TT 0.72 (0.45-1.14) 64 3 C vs T 0.97 (0.80-1.18) 68* 125,216,217
Random 1.23 (0.81-1.85) 0.75 (0.33-1.67) 0.99 (0.70-1.40)
SLC6A3 40bp VNTR 3 Fixed 9/10 vs 10/10 2.06 (1.25-3.40)** 0 9/9 vs 10/10 1.46 (0.67-3.16) 0 3 9 vs 10 1.38 (0.98-1.94) 0 67, 68
(DAT1) -31-UTR region Random 2.05 (1.24-3.40)** 1.47 (0.67-3.19) 1.38 (0.98-1.94)
SLC6A4 44bp Ins/Del 22 Fixed LS vs LL 1.05 (0.94-1.18) 0 SS vs LL 1.39 (1.20-1.61)** 0 24 S vs L 1.11 (1.04-1.19)** 30 (32,45,61-70,72-80)‡
(SERT) -Promotor Random 1.05 (0.93-1.18) 1.39 (1.20-1.61)** 1.12 (1.03-1.22)**
VNTR 8 Fixed 9/12 vs 12/12 1.25 (0.61-2.55) 0 9/9 vs 12/12 NA 0 11 9 vs 12 1.33 (0.78-2.27)* 0 14,42,52,69-77
Intron 2 Random 1.22 (0.58-2.56) NA 1.24 (0.69-2.23)
8 Fixed 10/12 vs 12/12 0.94 (0.74-1.20) 24 10/10 vs 12/12 1.17 (0.82-1.68) 11 10 vs 12 1.02 (0.89-1.17) 0 (14,35,190-199)
Random 0.98 (0.73-1.32) 1.18 (0.82-1.70) 1.04 (0.91-1.20)
TPH1 A218C 9 Fixed AC vs AA 1.10 (0.91-1.34) 49 CC vs AA 0.88 (0.71-1.09) 35 9 C vs A 0.94 (0.85-1.04) 6 68,94,146,151,218-221‡
Random 1.14 (0.85-1.52) 0.86 (0.65-1.14) 0.94 (0.84-1.05)
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Figure 4 Pooled odds ratios in relation to the total number of cases and controls included in 
the meta-analyses.
Odds ratios are reported for the per allele analyses.
Discussion
In this review we were able to perform meta-analyses for 18 out of 102 genes stud-
ied. We were not able to perform meta-analyses for 371 polymorphisms in 97 genes 
because there were less than three studies assessing the same polymorphism. We 
found significant evidence for five MDD susceptibility genes (APOE, GNB3, MTHFR, 
SLC6A3 and SLC6A4).
 The identified genes are involved in known biological pathways. The dopamine 
transporter (SLC6A3) mediates the active reuptake of dopamine from the synapse 
and is a principal regulator of dopaminergic neurotransmission. All antidepressants, 
in one way or the other, affect dopamine in the frontal area of the brain and in 
the nucleus accumbens.82-84 The protein encoded by the SLC6A4 gene is the drug 
target of serotonin reuptake inhibitors (SRIs) such as fluoxetine.85 The 44bp Ins/Del 
polymorphism is localized in the promotor region and may affect expression of the 
protein.86 GNB3 encodes for the beta subunit of G proteins, which is a target for anti-
depressant medication such as tricycles and MAO inhibitors.87 MTHFR is a plausible 
candidate since the MTHFR enzyme metabolizes folate, and lower folate levels have 
been found associated with depression.88 Furthermore, recovery from depression 
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may be enhanced by folate supplements.89 The most strongly associated gene in 
terms of the OR is APOE. APOE is recognized a major determinant in lipoprotein 
metabolism, cardiovascular disease, Alzheimer’s disease, cognitive function and im-
munoregulation,90 and as each of these disorders may be implicated in MDD, APOE 
remains at least a conceivable candidate gene to be studied further. 
 While these five genes were significantly associated to MDD in the meta-analyses, 
this does not mean the others may not be related. First, for many meta-analyses the 
total number of cases and controls studied was not large enough to detect moderate 
association to genes (OR ~1.2-1.5). For example, the pooled ORs of DRD3, HTR1A 
and SLC6A4 VNTR in intron 2 were 1.33-1.71, but not statistically significant. In 
terms of genetic effects for complex diseases, these are not small effects. In addition 
to small sample size, other reasons for the absence of statistical significance are the 
low frequencies of the risk variant and heterogeneity between studies. 
 Second, most studies have investigated only one single polymorphism per gene. 
Even if this single polymorphism appears not to be associated, there may still be 
other variants of the gene that are associated to MDD. The present meta-analyses 
only included two genes for which two polymorphisms were investigated (HTR2A 
and SLC6A4). The 44bp Ins/Del polymorphism of the SLC6A4 gene was found to be 
associated with MDD, while the VNTR in intron 2 of SLC6A4 was not. The latter 
shows that a negative meta-analysis of one polymorphism does not rule out signifi-
cant associations of other polymorphisms in the same gene. 
 Most research on the genetic origin of MDD has focused on a limited number 
of polymorphisms. Meta-analyses could only be performed for 22 of the 393 (6%) 
polymorphisms that had been investigated in relation to MDD. There were 371 
polymorphisms that were addressed in only one or two studies, while 13 studies 
investigating the HTR2C Cys23Ser polymorphism and 24 studies investigated the 
SLC6A4 44bp Ins/Del polymorphism. SLC6A4 has been reviewed in three previous 
meta-analyses,9,14,16 two showing no evidence for association with MDD. Differ-
ences between the meta-analyses may be explained by the inclusion of different 
studies, by heterogeneity between the results of individual studies, or by underesti-
mation of effect sizes due to bi-allelic (S/L) instead of tri-allelic (S/LG/L) grouping of 
the genotypes. The tri allelic grouping distinguishes two long alleles (LG/L), while the 
LG expresses similar to the S allele.
86 The high numbers of studies of these polymor-
phisms are exceptions. For most polymorphisms reviewed in the meta-analyses the 
number of available studies was still small, and most meta-analyses did not include 
enough studies to investigate sources of heterogeneity in a meta-regression, or per-
form formal tests of publication bias. Meta-regression analysis would be useful to 
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investigate whether the asymmetric funnel plots of the SLC6A4 44bp Ins/Del and 
APOE ε2 are suggestive of publication bias or indicate true heterogeneity between 
populations. This review clearly demonstrates that more MDD genetic association 
studies are needed.
 We excluded studies if they used questionnaires for the identification of cases, 
if they did not distinguish between MDD and bipolar depression, or if the genotype 
distributions in controls were not in Hardy-Weinberg equilibrium. Yet, we did not 
exclude studies or stratify the analyses based on other criteria, e.g., whether controls 
were selected from the general population or whether they had been screened for 
the absence of depression, because the number of studies for each polymorphism 
was small. Such differences between studies may have contributed to the hetero-
geneity that was found in several of the meta-analyses. To investigate causes of 
between-study heterogeneity in future meta-analyses, it is essential that individual 
studies report key characteristics of their populations. To accumulate the evidence 
in genetic-epidemiological studies harmonizing designs, populations and measure-
ments is deemed important and aimed for by the Network of Investigator Networks 
of the Human Genome Epidemiology Network.91 
 In conclusion, our meta-analyses found significant evidence for five MDD 
susceptibility genes (APOE, GNB3, MTHFR, SLC6A3 and SLC6A4). Together with 
our previously published meta-analysis on DRD4,12 there is evidence for six MDD 
susceptibility genes. The low coverage of genetic variants of candidate genes makes 
it impossible to exclude that the other genes studied are not involved in MDD. More 
research aiming to replicate findings in MDD is needed and efforts are required to 
standardize the methodology in research of MDD. 
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the Dopamine D4 receptor Gene 
48-base-pair-repeat polymorphism anD 
mooD DisorDers: a meta-analysis
Abstract 
Objectives: We conducted a meta-analysis to re-evaluate the role of the dopamine 
D4 receptor gene 48-base-pair-repeat (DRD4) polymorphism in mood disorders. 
Methods: DRD4 allele frequencies were compared between 917 patients with uni-
polar (UP) or bipolar affective disorder (BP), and 1,164 controls from twelve samples, 
using the Cochrane Review Manager. Results: An association was found between 
all mood disorder groups and DRD4.2. After correcting for multiple testing, the as-
sociation between DRD4.2 and BP dropped to insignificance, however the evidence 
of an association between the DRD4.2 allele and UP (p<0.001), and the combined 
group (p<0.001) remained. There was no evidence for heterogeneity or publication 
bias. Conclusions: These findings suggest that the DRD4.2 allele is a risk allele for 
depression symptomatology. 
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Introduction
Disturbances in dopamine neurotransmission have been found in mood disorders.1,2 
Animal,3,4 pharmacological,5-11 and post-mortem studies,12 suggest the dopamine 
D4 receptor gene (DRD4) as a candidate gene for mood disorders. The DRD4 gene 
is located on chromosome 11p15.5.13 The gene contains a functional polymorphism 
consisting of two to ten 48-bp-repeats in the third exon.14
 The role of the DRD4 in mood disorders has been researched in a large number 
of studies, but the findings are not consistent. Significant associations have been 
reported between DRD4 alleles with unipolar depressive disorder (UP),15 and with 
bipolar depressive disorder (BP).16,17 However, others did not confirm these find-
ings.10,18-27 It remains possible that these studies were underpowered due to their 
small sample size.28 
 The aim of this study is to re-evaluate if there is an association of the dopamine 
D4 receptor gene 48-base-pair-repeat (DRD4) polymorphism with UP or with BP by 
performing a meta-analysis.
Methods and Materials
Identification of studies
We searched Medline for all publications available up to February 2004 studying the 
association between the DRD4 48-bp-repeat polymorphism and mood disorders 
with the keywords mood, affective, unipolar, bipolar, depression, DRD4 and D4. 
References from retrieved publications were checked for any additional studies. 
Seventeen articles were identified.10,15-26,29-32 Three articles used a family-based 
design.17,18,24 
 In order to include the studies with the same methodological and statistical tech-
niques, we limited the analysis to studies using a case-control design and studies that 
reported allele frequencies. Studies with overlapping cases were excluded,19,26,29,31,32 
to only include the study with the largest number of cases.25 The included studies 
are listed in Tables 1 and 2.
 We distinguished three groups of cases: UP, BP, and both combined. In total, 318 
patients and 814 control individuals from 5 studies were included in the UP meta-
analysis.10,15,20,25 In the BP meta-analysis, seven studies were included.10,15,16,21,23,25 
In total, 599 patients with BP were compared to 992 control individuals. In the 
combined group, 917 patients and 1,164 control individuals were entered.
Statistical Analysis
Hardy-Weinberg equilibrium was examined in studies where genotype frequencies 
were included.15,16,20,21,25 We examined the effects of the three most prevalent 
alleles: 
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two-repeat (DRD4.2), four-repeat (DRD4.4), and seven-repeat (DRD4.7). In addition 
we examined the association of mood disorders with short (one-repeat to four-repeat) 
versus long alleles (five-repeat to ten-repeat), a definition commonly used.21,29 For all 
the meta-analyses we used the Cochrane Review Manager (RevMan) version 4.2 and 
analyzed them with RevMan analysis 1.0.1. The method of moments was applied to 
calculate the odds ratio (OR) in a random-effects model for the pooled data.33 The 
p level, adjusted for multiple testing, was considered significant when lower than 
0.003 (Bonferroni corrected: p=0.05/15, to justify for the three groups and the five 
genotypic subgroups tested).
 RevMan was also used to produce funnel plots to examine publication bias. The 
method is based on the fact that precision in the estimation of the true effect in-
creases as sample sizes of the studies increase. OR, representing the relative effects 
estimated from individual studies (x axis), is plotted against the standard error on a 
logarithmic scale as a measure of each study’s sample size (y axis). This takes into 
account that the statistical power of a trial is determined both by its total sample 
size and the number of outcomes. In the absence of bias the plot should resemble a 
symmetrical inverted funnel, hence the name.34,35 
Results
All studies used structured diagnostic interviews. One study,15 used the DSM-III-R 
criteria,36 all the other studies applied the RDC.37,38 
 DRD4.4 was the most prevalent allele in all patients and control individuals, while 
the DRD4.7 allele was not present in the Japanese population. The proportion of al-
leles and genotypes of one control sample in the UP group, and two control samples 
in the BP group, were not consistent with HWE.15,16 Therefore we performed the 
analyses both including and excluding these studies. The exclusion of these samples 
did not materially change the results. One bipolar study did not include genotype 
frequencies,16 therefore it was not possible to test for HWE in this study. 
 Table 3 presents OR and p values for the pooled analyses of the DRD4 alleles 
studied. An association was found between all mood disorder groups and DRD4.2. 
After correcting for multiple testing, the association between DRD4.2 and BP dropped 
to insignificance, however the evidence of an association between the DRD4.2 allele 
and UP (p<0.001), and the combined group (p<0.001) remained. No association was 
observed with the other alleles tested or when divided into short and long alleles.
chaPter 3
54
Figure 1 Relation between Unipolar (UP), Bipolar (BP) and the DRD4.2 48bp-repeat poly-
morphism
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Figure 2 Funnel plots for Unipolar (UP) and Bipolar (BP) groups
Table 3 Relation between Unipolar (UP), Bipolar (BP) and the DRD4 48bp-repeat poly-
morphisms
Allele Mood Disorder OR CI p value
DRD4.2 Unipolar 1.73 1.29-2.32 0.0003*
Bipolar 1.26 1.01-1.57 0.04
Unipolar + Bipolar 1.41 1.18-1.68 0.0002*
DRD4.4 Unipolar 0.88 0.72-1.09 0.24
Bipolar 0.88 0.75-1.04 0.13
Unipolar + Bipolar 0.88 0.78-1.00 0.06
DRD4.7 Unipolar 0.70 0.53-0.94 0.02
Bipolar 1.03 0.82-1.30 0.80
Unipolar + Bipolar 0.89 0.74-1.06 0.18
Short Unipolar 1.23 0.89-1.70 0.22
Bipolar 0.95 0.77-1.17 0.60
Unipolar + Bipolar 1.02 0.86-1.22 0.80
*significant after Bonferroni correction p < 0.003, 1 
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Figure 1 presents the OR for the individual studies and the pooled analyses for the 
DRD4.2 allele. Of note is that all UP studies showed a consistent increase in OR 
while for BP five out of seven studies showed an OR higher than 1. For both UP 
and BP there was no evidence for heterogeneity in ORs across studies. Figure 2 
presents the funnel plots of the DRD4.2 allele. The plot for the UP group is quite 
symmetric, but this is not the case for the BP group. More BP negative results have 
been published as compared to positive ones. 
Discussion 
In this study we pooled the data of 917 patients and 1,164 control individuals to re-
evaluate the association between the DRD4 48-bp-repeat polymorphism and mood 
disorders. The results of our study showed a significant association between DRD4.2 
allele in two groups: UP, and UP and BP combined. These findings suggest that the 
DRD4.2 allele is a risk allele for depression symptomatology.
 Association studies have been widely used to identify susceptibility genes.39 
There is increasing evidence that small sample sized association studies lack statisti-
cal power and have resulted in apparently contradicting past findings.28 Ioannidis 
and Lohmueller found that, when combining association studies with contradictory 
results, approximately 20-30% of genetic association studies were statistically sig-
nificant.40,28 The use of meta-analysis is an important step in reconciling previously 
conducted studies with inconsistent results. 
 In our study there is no evidence of heterogeneity across studies, even though 
we included populations of Europe, Israel, China and Japan. Ethnicity was not as-
sociated with the DRD4.2 allele frequency, making it unlikely that ethnicity was a 
confounder in this meta-analysis. Both random-effect and fixed-effect models gave 
the same results, further supporting the absence of heterogeneity.41 A limitation of 
meta-analysis is publication bias because the likelihood of publishing a study could 
be related to the positive results of the study.35 The funnel plot in the UP group is 
quite symmetrical, showing no evidence of publication bias. The funnel plot in the 
BP group shows a small excess of negative studies published. This may have biased 
our finding towards an OR of 1. 
 We only included population-based studies and excluded family-based studies 
because of their different methodology. Another reason is that none of the three 
family-based studies assessed UP; they focused on BP yielding no significant re-
sults.17,18,24 The exception is the study of Serretti et al 2002, which also included a 
combined BP and UP group, reporting a p=0.037 for DRD4.2. This was not reported 
as significant since a p value of 0.0125 was set after Bonferroni correction. However 
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this finding does not exclude the association we observed. All results of the three 
family-based studies are consistent with our findings. 
 DRD4 is expressed in many regions of the body, with a high level of expression 
in the frontal area of the brain and in the nucleus acumbens,2,42-44 areas associated 
with anhedonia, lack of motivation, and affective and emotional behaviors.2 It has 
been observed that all antidepressants, in one way or the other, affect dopamine 
in these areas,3,45-48 and that D4 receptor agonists,45,49-53 such as methylpheni-
date,54-58 have antidepressant properties. 
 The mechanism by which dopamine D4 receptor expression is regulated is not 
yet fully understood,59 and much of the research has focused particularly on DRD4.7, 
since this allele has been consistently associated with ADHD, schizophrenia, and 
novelty-seeking.60-62 One of the most studied functions of the D4 receptors is that 
they inhibit adenylyl cyclase activity and thereby reduce conversion of ATP into 
cAMP.63-69 It has been reported that dopamine DRD4.2 receptors are less potent 
than the DRD4.4 or the DRD4.10 in coupling to adenylyl cyclase, and show a blunted 
ATP to cAMP conversion.42,64,65 D4 receptors with a sub-optimal functionality – as 
seen with DRD4.2 – may account for symptoms of depression.
 Another issue to consider is genetic imprinting, it has been suggested in par-
ticular for BP.70,71 Such a mechanism may explain why the power of the studies is 
low. However Van Broeckhoven et al 1999, have not found evidence for genetic 
imprinting in BP and to our knowledge there is no evidence in UP.
 In summary, we found evidence of a positive association between the DRD4.2 
allele in two groups: UP, and UP and BP combined. These results show that meta-
analysis can overcome the low power of small sample size studies, which are char-
acteristic of genetic association studies. Thus, our meta-analysis strongly shows that 
DRD4 cannot be excluded as a susceptibility gene for mood disorders.
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Abstract 
The ACE I/D polymorphism has been studied as a candidate gene for major depression, 
but findings are inconsistent. To re-evaluate this association we conducted a case-
control study and a meta-analysis. The case-control study was embedded within the 
Rotterdam Study, a population-based cohort of subjects aged 55 years and older. For 
the meta-analysis, we searched Medline for studies on the association between the 
ACE I/D polymorphism and major depression. We calculated odds ratios to compare 
genotype frequencies between cases and controls. The case-control study included 
64 cases and 3,980 controls. The meta-analysis comprised six studies, encompassing 
586 cases and 5,169 controls. No evidence was found for an association between 
the ACE I/D polymorphism and major depression in either study. Our results indicate 
that the ACE I/D polymorphism is not associated to major depression. 
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Introduction
Several lines of evidence in experimental, pharmacological and physiological 
research 1-3 suggest that the angiotensin converting enzyme (ACE) is involved in 
major depression. Furthermore, it is well known that the ACE gene is involved in 
the metabolism of the neuropeptide substance P, which in turn is involved in the 
regulation of affective behavior.4 The gene that codes for ACE is located on chromo-
some 17q23. It contains a polymorphism that has either an insertion or a deletion 
(I/D) of a 287 base-pairs fragment in the 16th intron. The ACE gene has been studied 
as a candidate gene for major depression, but findings are inconsistent. Arinami et 
al. reported an increased risk of major depression for individuals carrying the ACE 
D homozygous genotype (ACE DD), and a higher level of substance P in subjects 
with this genotype.4 Later studies were unable to replicate this finding,5-8 although 
one observed a higher risk associated with the ACE heterozygote genotype (ACE 
ID).8 Most studies were of limited size (n<200) raising the question whether lack of 
statistical power explains the negative findings.
 We conducted a case-control study on the relationship between the ACE I/D 
polymorphism and major depression in a population-based cohort. Additionally we 
combined all available studies in a meta-analysis to investigate the overall evidence 
for a role of the ACE gene in major depression. 
Methods
Case-Control Study
The cross sectional case-control study was embedded within the Rotterdam Study, 
a population based cohort of subjects aged 55 years and older (n=7,983).9 All par-
ticipants gave informed consent and the Medical Ethical Committee of the Erasmus 
University Medical Center approved the scientific protocols. Cases and controls 
were selected among subjects who participated in the third assessment of the cohort 
(n=4,797). A total of 4,652 subjects (97%) completed the Center of Epidemiological 
Studies Depression Scale (CES-D) and underwent extensive medical examinations. 
All participants with a CES-D score higher than 16 (n=336, 7.2%) were subsequently 
evaluated according to the DSM-IV using the Schedules for Clinical Assessment in 
Neuropsychiatry. Cases (n=64) were subjects who fulfilled the DSM-IV criteria for 
major depression. Controls (n=3,980) were subjects who scored lower than 16 on the 
CES-D and had no history of depression.
 DNA was isolated from blood samples using salting out method standard proce-
dures. The II, ID, and DD genotypes were detected by using the polymerase chain-
reaction (PCR) technique. The relationship between the ACE I/D polymorphism and 
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major depression was assessed by odds ratios (ORs) using logistic regression analysis 
adjusting for age and sex. ORs with 95% confidence intervals (CI) were calculated 
for the ID and DD genotypes using the II genotype as the reference group. Analyses 
were performed on SPSS software version 11.5 (SPSS, Chicago, USA). 
Meta-analysis
For the meta-analysis, we searched Medline for case-control and cohort studies on 
the association between the ACE I/D polymorphism and major depression published 
before October 2005. The search strategy was based on the key words mood, af-
fective, unipolar or depression combined with angiotensin or ACE. We limited our 
search to human populations and articles written in English. References in retrieved 
articles were screened for additional studies. 
 Pooled ORs were calculated for the ID and DD genotype using random-effects 
models of DerSimonian and Laird taking the II genotype as the reference group. The 
degree of heterogeneity between the study results was tested with the chi-square test. 
Publication bias was evaluated by examination of funnel plots. The meta-analysis 
was performed with the Cochrane Review Manager Version 4.2. P values lower than 
0.05 (two-tailed) were considered statistically significant.
Results
Case-Control Study
The study population consisted of 64 unrelated cases of major depression (preva-
lence=1.4%; mean age=76.2 years, SD=7.8; 30% men) and 3,980 controls (mean 
age=72.7 years, SD=7.3; 43% men). There were no significant differences in the 
frequencies of the ACE alleles and the genotypes between cases (II=28%, ID=42%, 
DD=30%) and controls (II=22%, ID=51%, DD=27%). We found no statistically 
significant association to major depression for either the ID genotype (adjusted 
OR=0.61, 95% CI=0.33-1.12, p=0.11) or the DD genotype (adjusted OR=0.80, 95% 
CI=0.42-1.54, p=0.50).
Meta-analysis
Of the 362 articles retrieved, six investigated the association of the ACE I/D poly-
morphism and major depression. All were case-control studies. These and the case-
control study from this paper were included in the meta-analysis. The genotype 
frequencies of cases and controls were in Hardy Weinberg Equilibrium. All studies 
used structured diagnostic interviews based on the DSM-III-R or DSM-IV criteria.
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Figure 1 Meta-analysis on the association between the ACE I/D polymorphism and major 
depression
A total of 586 cases and 5,169 controls were included. The ORs (95% CI) of the 
individual studies and the pooled results are presented in Figure 1. The pooled OR 
was 0.85 (95% CI=0.55-1.30) for the ID genotype and 1.01 (95% CI=0.71-1.45) for 
the DD genotype. Both ORs were not statistically significant (p>0.05). There was 
significant heterogeneity between studies for the ID genotype (Chi2=14.22, df=5, 
p=0.01), but not for the DD genotype (Chi2=7.11, df=5, p=0.21), meaning that for the 
ID genotype the results of the individual studies differed more than what would be 
expected by chance. The positive association reported by Bondy et al 8 introduced 
heterogeneity by acting as an outlier in our analysis. The exclusion of the study did 
not materially change the results. The funnel plot showed a symmetrical distribution, 
indicating there is no evidence  for publication bias. 
Discussion 
In this meta-analysis we pooled the data of 586 depressed cases and 5,169 controls 
from available published studies to re-evaluate the association between the ACE I/D 
polymorphism and major depression. We found no evidence of association. This 
meta-analysis demonstrates that the contradicting findings on the relation between 
ACE I/D polymorphism and major depression were not due to small sample sized 
populations.
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ACE is a component of the renin angiotensin system (RAS), a system that is assumed 
to be involved in depression. Evidence for this relationship comes from research 
showing that ACE inhibitors have antidepressant effects,10 antidepressants block ATII 
effects,11 and the RAS modulates the hypothalamus-pituitary-adrenocortical axis by 
stimulating corticotrophin hormones.12 Of all the genes in the RAS, the ACE is the 
only gene that has been investigated in relation to depression. The results of our 
study show conclusively that the ACE gene does not play a direct role in symptoms of 
depression. Given the role of the RAS in the etiology of depression, we recommend 
that future research should explore the contribution of other genes in this system. 
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anGiotensinoGen m235t polymorphism 
anD symptoms of Depression 
in a population-baseD stuDy anD a 
family-baseD stuDy
Abstract 
Background: Evidence suggests that the angiotensinogen (AGT) gene is involved in 
depression. The aim of this paper is to examine the association between the AGT 
M235T polymorphism and symptoms of depression in two independent populations, 
a population-based study, and a family-based study. Method: Symptoms of depres-
sion were scored using the Center of Epidemiological Studies Depression Scale 
(CES-D) and compared between the MM, MT, and TT genotype groups. The extent 
to which AGT M235T explains the heritability of the scores was examined using 
a variance components analysis. Results: A significant relation between the AGT 
M235T polymorphism and CES-D scores was found in men in both populations. 
The heritability estimate was 32%. The AGT genotype contributed to 1% of the total 
variance of the CES-D scores. Conclusions: Our findings suggest that the AGT gene 
is involved in the etiology of symptoms of depression in men.
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Introduction
While there is substantial evidence for the involvement of the renin angiotensin 
system (RAS) in depression,1-4 little is known about whether specific RAS genes are 
involved. Investigations have focused mainly on the ACE and AGT genes. In a recent 
meta-analysis of 6 studies we demonstrated that the ACE gene is not associated with 
major depression.5 Evidence for a role of the AGT gene is still minimal. A population-
based study demonstrated that the M allele of the AGT M235T polymorphism was 
associated with bipolar depression,6 knock-out mice lacking the AGT gene have a 
reduction of depressive-like behaviours,7 and a significant linkage of mood disorders 
was found on chromosome 1q42 (LOD score=4.5), the area where AGT is localized.8 
The aim of our study was to further investigate the association of the AGT M235T 
polymorphism with symptoms of depression in two independent populations: a 
population-based study, and a genetically isolated family-based study. 
Methods
Study populations and procedures
The population-based study was conducted within the Rotterdam Study, a cohort 
study in the Netherlands of 7,983 men and women aged 55 years and older. Baseline 
data were collected from 1990 to 1993. Analyses were performed on data from 
individuals who participated in the fourth assessment of the study (n=3,550), which 
took place from 2002 to 2004. 
 The family-based study was embedded in the Erasmus Rucphen Family Study, 
which is part of the Genetic Research in Isolated Populations programme. This study 
investigates the genetic origin of complex genetic disorders and traits in a geneti-
cally isolated community in the Southwest of the Netherlands. Genealogical data 
of this community date back to the middle of the sixteenth century. All descendants 
from 20 couples living in the isolate from 1850 to 1900 were ascertained and living 
descendants of 18 years and older were invited to participate. Data were collected 
from 2002 to 2005. 
 In both studies participants underwent extensive medical examinations and com-
pleted several questionnaires. The studies have been previously described.9-10 The 
Medical Ethical Committee of the Erasmus University Medical Center approved both 
studies and all participants gave informed consent.
Measurements
Symptoms of depression were assessed using the Center of Epidemiological Stud-
ies Depression Scale (CES-D). The CES-D is a 20-item inventory that measures the 
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presence and severity of symptoms of depression. The psychometric properties of 
the CES-D score have been well established.11 Total scores range from 0 to 60 with 
higher scores indicating more symptoms of depression. We used the CES-D score as 
a continuous scale. 
 The medical examination included assessments of height, weight, blood pressure 
and medication use. Blood pressure was taken twice in the sitting position from the 
right upper arm. The average of the two measurements was used as a continuous 
variable. Hypertension was defined as mean systolic blood pressure higher than 
160 mmHg, mean diastolic blood pressure higher than 100 mmHg or the use of 
antihypertensive medication.
Genotyping
DNA was isolated from blood samples using standard procedures (salting out 
method).12 The MM, MT, TT genotypes of the AGT M235T polymorphism were 
detected using a set of oligonucleotide primers flanking the polymorphic site in exon 
2 (forward primer, 5’CTG GCT CCC ATC AGG3’, reverse primer, 5’CTG GCT CCC 
GTC AGG3’). 
Statistical analysis
To examine the effect of the AGT genotype on symptoms of depression, mean CES-D 
scores were compared between AGT genotype groups by regression analysis adjust-
ing for age, sex, and use of antidepressant medication. Since the CES-D score was 
not normally distributed, a square root transformation was applied in the analysis. As 
the results did not change with or without the transformation, we report in this paper 
the CES-D score without the transformation for ease of interpretation. 
 The heritability of the CES-D scores was estimated using a variance component 
analysis that was adjusted for age, sex, and antidepressant medication. To investigate 
the extent to which AGT M235T contributes to the heritability of the CES-D, we re-
peated the analysis with AGT genotype status as a covariate. Dummy variables were 
created for the MT and TT genotypes, thereby taking MM genotype as the reference 
group. In addition, to investigate whether symptoms of depression increased with 
the number of T alleles present (p for trend), we considered genotype status as a 
continuous variable by the number of risk alleles.
 The contribution of the AGT genotype in the total variance of CES-D was quanti-
fied by estimating the difference in the proportion of variance explained by the 
covariates of the two analyses, and tested using the likelihood ratio test for the differ-
ence between the two analyses (χ2 statistic at 2 degrees of freedom). 
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To investigate if hypertension is an intermediate factor in the relationship between 
AGT genotype and depression we repeated the analyses including hypertension. All 
analyses were performed using SPSS software, version 11.5 (SPSS, Chicago, USA) 
for the population-based analysis and SOLAR 2.1.2 (software package Southwest 
Foundation for Biomedical Research, San Antonio, Texas, USA) for the family-based 
analysis.13 P values lower than 0.05 (two-tailed) were considered statistically signifi-
cant.
Results
Population-based study
Of 3,550 persons who participated in the fourth assessment of the Rotterdam Study, 
3,134 persons (88%) completed the CES-D questionnaire and had genotype informa-
tion available. The mean age of the participants was 75.9 years (SD ± 6.4) and 41% 
were men. General characteristics of the participants are presented in Table 1. The 
distribution of the AGT genotypes was in Hardy Weinberg Equilibrium (p=0.32). 
There were no statistically significant differences in allele or genotype frequencies 
between men and women (Table 2).
 The mean CES-D scores are presented overall and stratified by men and women 
(Figure 1). Individuals with the MT and TT genotypes had significantly higher CES-D 
scores than individuals with the MM variant (p<0.05). The stratified analysis showed 
that mean CES-D scores differ between the genotype groups in men, but not in 
women. In men, the mean CES-D score for the MM carriers was 4.6 (SD±7.0), for the 
MT carriers 5.5 (SD±6.9), and for the TT carriers 6.7 (SD±6.9). Men with the MT and 
TT genotypes had significantly higher CES-D scores than individuals with the MM 
variant (p<0.05). CES-D scores in men increased with the number of T alleles present 
(p for trend <0.001). 
Family-based study
Out of 825 relatives, 783 persons (95%) completed the CES-D questionnaire and had 
genotype information available. The mean age was 52.0 years (SD±14.5) and 41% of 
the participants were men. The age ranged from 18 to 89 years because the partici-
pants comprised three generations. General characteristics for men and women are 
presented in Table 1. The distribution of the AGT genotypes was in Hardy Weinberg 
Equilibrium (p=0.88). There were no statistical significant differences in allele or 
genotype frequencies between men and women (Table 2).
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Table 1 General characteristics of the study populations
Population-based study Family-based study
 
Men
(n = 1,279)
Women
(n = 1,855) p value
Men
(n = 318)
Women
(n = 465) p value
Age, years 75.3 (6.0) 76.3 (6.6) < 0.001 53.6 (14.0) 50.8 (14.7) 0.01
CES-D score 5.4 (6.7) 8.3 (8.6) < 0.001 10.4 (10.1) 12.3 (10.4) 0.01
Use of antidepressants 3.4 6.5 < 0.001 5.0 10.1 0.01
Hypertension 49 50 0.18 47 43 0.13
Use of antihypertensives 29 26 0.06 37 35 0.49
Level of Education
Elementary school 33 57 72 67
Intermediate education 48 38 < 0.001 22 30 0.01
Higher education 19  5  6  3
Body mass index, kg/m2 27.0 (3.4) 27.7 (4.5) < 0.001 27.4 (4.1) 26.5 (4.7) 0.01
Values are mean (standard deviations) for continuous variables and percentages for categorical variables.
p values obtained by ANOVA for continuous variables and χ2 for categorical variables.
CES-D: Center of Epidemiological Studies Depression Scale.
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Figure 1 Mean CES-D scores adjusted for age and antihypertensive medication by AGT geno-
types
Figure 1 shows mean adjusted CES-D scores stratified by AGT genotype for the 
overall group and for men and women separately. In this population we also found 
that among men, the CES-D scores increased with the number of T alleles present 
(p for trend=0.01). Men with the TT genotype had significantly higher CES-D scores 
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than individuals with the MM variant (p=0.01). For men the mean scores of the 
CES-D increased from 9.8 (SD±9.7) for the MM carriers to 13.9 (SD±9.7) for the 
TT carriers. No relationship between AGT genotype and CES-D scores was found 
among women. 
 The heritability of the CES-D scores was 32% (p<0.001) and the proportion of 
variance explained by all covariates was 0.09. When AGT genotype status and the 
genotype multiplied sex interaction were included in the analysis, the heritability 
estimates changed to 31% (p<0.001). The proportion of variance explained by all 
covariates changed to 0.10 indicating that the AGT genotype contributed to 1% of 
the total variance in the CES-D scores. Neither in the regression analyses nor in the 
heritability analysis did the effect of AGT change when hypertension was added 
to the model, indicating that hypertension is not an intermediate variable in the 
relationship between AGT and depression.
Table 2 Genotype and allele frequencies in the two study populations
Population-based study Family-based study
Men Women Men Women
(n = 1,279) (n = 1,855) p value (n = 318) (n = 465) p value
Genotype frequency, in % (n)
MM 37 (473) 36 (676) 0.55 27 (87) 27 (126) 0.99
MT 48 (609) 47 (866) 50 (160) 50 (233)
TT 15 (197) 17 (313) 22 (71) 23 (106)
Allele frequency, in % 
M 61 60 0.39 53 52 0.50
T 39 40   47 48  
HWE = Hardy Weinberg Equilibrium
Adjusted for age, sex degree of consanguinity and use of antidepressant medication
Discussion
In two independent populations we found that the AGT M235T polymorphism was 
associated with symptoms of depression in men. In the population-based study men 
with the MT or the TT genotype reported significantly more symptoms of depression 
than those with the MM genotype, and in the family-based study men carrying the 
TT genotype had a higher level of symptoms of depression. Furthermore, we dem-
onstrated that the AGT gene accounts for 1% of the overall variance in symptoms of 
depression. 
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Before discussing the implications of our findings, one methodological issue needs 
to be addressed. In the population-based study we found that carriers of the T allele 
(MT and TT genotype) on average had significantly higher CES-D scores than those 
with the MM genotype, while in the family-based study only individuals with the 
TT genotype had significantly higher CES-D scores. While the studies may suggest 
different modes of inheritance for the relationship between AGT and depression, 
these findings could be due to the age differences between the two cohorts. The 
weaker effect in heterozygous carriers could be attributable to the younger age of 
the family-based cohort, as symptoms of depression may appear at a later age. The 
stronger effect in homozygous carriers may become apparent earlier in life, and 
hence showed up in both of our populations. In both populations, we only found an 
association between the AGT M235T polymorphism and symptoms of depression 
in men. 
 Given that in both populations women had higher depression scores than men, 
it can be argued that other causal factors may outweigh the role of AGT in women 
and mask an eventual effect of the gene in this subgroup. Yet, there is some earlier 
evidence that the RAS may have different roles in the etiology of depression for men 
and women. For example, a study suggested gender differences in RAS regulation 
between men and women because in contrast with earlier studies that found an 
increase in aldosterone and renin plasma concentrations in depressed men,14,15 they 
found no differences in these concentrations in women.16 Another study found an 
association between panic disorders and men carrying the AGT T allele, this associa-
tion was not found in women.17 
 The AGT gene has been widely studied for its relationship with hypertension.18 
We studied whether increased blood pressure was an intermediate factor in the 
relationship between AGT and symptoms of depression, but we found no evidence 
for this. An alternative mechanism that could explain the association of the AGT 
gene with depression is the relationship of RAS with the hypothalamic pituitary 
adrenal (HPA) axis. RAS directly modulates the HPA axis by stimulating corticotro-
phin hormones.19,20 The presence of the T allele of the AGT gene increases the 
angiotensinogen level,21 this increase could enhance the HPA feedback and lead 
to symptoms of depression. In depressed patients there has been a consistent find-
ing suggesting hyperactivity of the HPA axis increases both corticotrophin releasing 
hormone (CHR) and adrenocotropic hormone (ACTH). This feedback leads to high 
amounts of cortisol and aldosterone,22 which are typically seen in patients with 
depression.23
chaPter 5
74
The only study that has evaluated the relationship between the AGT gene and af-
fective disorders found that the M allele was associated with bipolar disorder and 
stated that the TT genotype could have a protective effect for bipolar disorder.6 
We particularly found that individuals with the TT genotype had higher levels of 
symptoms of depression than those with the M allele, which seems to contradict the 
study on bipolar depression. It can be argued that the presence of manic episodes 
suggest different pathophysiological mechanisms are involved in bipolar depression. 
For example, when the TT genotype upregulates the RAS and increases the risk for 
depression,21 it can be speculated that the MM genotype downregulates the RAS 
and increases the risk for mania. 
 In conclusion we found that the AGT M235T polymorphism is associated with 
symptoms of depression in two independent populations, which supports the role of 
the AGT gene and the RAS in the etiology of mood disorders. In both the population-
based and the family-based study, the association was only found in men, which 
suggests that the RAS may have a different causal role in depression among men and 
women. This finding contributes to the understanding of the pathogenesis of mood 
disorders, and may open new avenues to our understanding and treatment of mood 
disorders. 
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Genetic factors influence the clusterinG of 
Depression amonG inDiviDuals with lower 
socioeconomic status
Abstract
Background: Depression and socioeconomic status are both partly determined by 
genetic factors. We aimed to investigate the role of shared genetic factors in the co-
occurrence of symptoms of depression and socioeconomic status, and to examine if 
neuroticism or intelligence are involved in these pathways. Methods: Subjects were 
2,383 participants of the Erasmus Rucphen Family Study. Symptoms of depression 
were assessed using the Center for Epidemiologic Studies Depression Scale (CES-D) 
and the Hospital Anxiety and Depression Scale (HADS-D), premorbid intelligence 
by the Dutch Adult Reading Test (DART) and neuroticism by the NEO-Five Factor 
Inventory. Socioeconomic status was obtained as the highest level of education. The 
role of shared genetic factors was quantified by estimating genetic correlations (ρG) 
between symptoms of depression and education level, with and without adjustment 
for DART premorbid intelligence and NEO-FFI neuroticism scores. Results: Higher 
level of education was associated with lower depression scores (partial correla-
tion coefficient -0.09 for CES-D and -0.17 for HADS-D). Significant genetic cor-
relations were found between education and both CES-D (ρG=-0.65) and HADS-D 
(ρG=-0.50). The genetic correlations remained statistically significant after adjusting 
for premorbid intelligence and neuroticism scores. Conclusions: Our study suggests 
that shared genetic factors play a role in the co-occurrence of lower socioeconomic 
status and symptoms of depression. 
6
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Introduction
Depression is the leading cause of disability among individuals between 15 to 44 
years of age, and is expected to become the second leading source of disability 
across all ages by 2020.1 While depression occurs in individuals from all layers of so-
ciety, there is consistent evidence that the prevalence of depression is higher among 
individuals with lower socioeconomic status.2 
 The nature of the clustering between depression and socioeconomic status is 
multifactorial.2,3 Lower socioeconomic status may increase the risk of depression, as 
individuals from lower socioeconomic levels tend to have more stressful life events, 
poorer coping styles, and weaker social support networks, which put them at in-
creased risk of developing depression.4 Alternatively, depression may lead to lower 
socioeconomic status, for example depression in young adulthood may increase the 
risk of job loss, and lead to lower socioeconomic status and depression later in life.3 
Another hypothesis is that the clustering of depression and lower socioeconomic sta-
tus is explained by shared causal pathways that lead to depression and lower socio-
economic status. For example, serotonin and dopamine pathways have been found 
to be involved in both traits and may be involved in both traits independently.5,6 
Alternatively, low intelligence or neuroticism may share causal determinants as they 
are closely related to symptoms of depression and socioeconomic status. It has been 
known for long that neurotic persons are more vulnerable to depression,7 and that 
persons with lower intelligence have a lower socioeconomic status.7,8 Further there is 
some evidence that higher levels of neuroticism are associated with lower academic 
performance,9 and that lower intelligence is associated with a slight increase in the 
risk of depression.10 
 When shared causal pathways are involved in the co-occurrence of depression 
and lower socioeconomic status, shared genes in these pathways may also be im-
portant. Both depression and socioeconomic status are partly determined by genetic 
predisposition. Heritability estimates range from 0.30 to 0.50 for socioeconomic 
status,11-14 and from 0.17 to 0.78 for depression,15 depending on the population 
investigated. The first aim of this study was to investigate the extent to which shared 
genetic factors can explain the clustering of depression among individuals with lower 
socioeconomic status. The second aim of the study was to examine if neuroticism or 
intelligence are involved in the clustering.
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Subjects and methods
Subjects 
Subjects were participants of the Erasmus Rucphen Family (ERF) Study, a family-
based study that investigates the genetic origins of complex diseases in a genetically 
isolated community in the Southwest of the Netherlands. The study population es-
sentially consists of one extended family, whose members are descendants from 20 
related couples that lived in the isolate in the period between 1850 and 1900. All 
descendants were ascertained and descendants of 18 years and older were invited 
to participate. Spouses were invited only for family members that had children of 18 
years and older. 
Procedures 
All participants filled out questionnaires and underwent extensive medical ex-
aminations at the research center. The examinations were done by physicians of the 
academic center according to a standardized research protocol. Level of education, 
symptoms of depression, personality and premorbid intelligence were ascertained by 
questionnaires. Participants were asked to bring all medication to the research center 
and the use of antidepressant medication was verified by the physician. Data were 
collected between 2002 and 2005. The study was approved by the Medical Ethical 
Committee of the Erasmus University Medical Center Rotterdam and all participants 
gave informed consent. 
Measurements
Symptoms of depression were assessed using the Center for Epidemiologic Studies 
Depression Scale (CES-D),16 and the depression subscale of the Hospital Anxiety De-
pression Scale (HADS-D).17 Both scales are valid and reliable self-report measures of 
symptoms of depression.18 The CES-D consists of 20 items with total scores ranging 
from 0 to 60, and the HADS-D of 7 items with scores ranging from 0 to 21. Higher 
scores indicate more symptoms of depression.
 Socioeconomic status was assessed as the highest level of education.2 Seven 
education levels were distinguished and ranked from one (unfinished elementary, 
grade or primary school) to seven (college or university). Premorbid intelligence was 
assessed using the validated Dutch Adult Reading Test (DART).19 DART premorbid 
intelligence scores range from zero to 100 with higher scores indicating higher levels 
of premorbid intelligence. Neuroticism was measured using the NEO five factor 
inventory (NEO-FFI), a validated self-report questionnaire addressing five core per-
sonality traits.20 The NEO-FFI neuroticism scale consists of 12 statements with total 
scores ranging from 0 to 48. Higher scores indicate higher levels of neuroticism. 
chaPter 6
82
Statistical analysis
General characteristics were compared between men and women and tested using 
ANOVA for continuous variables and chi-squared test for dichotomous variables. To 
quantify the strength of the phenotypic association between symptoms of depression 
and education, partial correlations (ρ) were calculated adjusting for age, sex, degree 
of consanguinity and the use of antidepressant medication. Multiple linear regres-
sion models were fitted to examine the association of covariates with symptoms of 
depression and to assess the distributional assumption of normality. The normality 
of residuals was tested using a one-sample Kolmogorov-Smirnov test. These analyses 
were performed using SPSS 11.0 for Windows. 
 Heritability estimates (h2) were calculated as the ratio of the variance of the trait 
explained by additive polygenic effects to the total phenotypic variance of the trait. 
Bivariate analyses were performed to estimate the genetic and environmental cor-
relations between the symptoms of depression and education.21,22 The genetic and 
environmental correlations can be calculated from the phenotypic correlations (ρP) 
by the following formula ρP = [square root]h12[square root]h22ρG + [square root]
(1-h1
2)[square root](1-h2
2)ρE,23,24 where h12 and h22 are the heritability estimates of 
the traits for which the phenotypic correlation is calculated, and ρG and ρE are the 
genetic and environmental correlations between these two traits. Significance of the 
additive genetic and environmental correlations was determined using a likelihood 
ratio test. To test whether a given correlation between two traits was significantly dif-
ferent from zero, the likelihood of a model in which this correlation was constrained 
to zero was compared with a model in which the same correlation was estimated. 
Twice the difference in ln-likelihoods of these models yields a test statistic that is 
asymptotically distributed as a chi-squared statistic with degrees of freedom equal to 
the difference in number of parameters estimated in the two models. 
 Analyses were adjusted for age, sex, use of medication, degree of consanguinity 
and sibship effects. The degree of consanguinity, indicating the degree to which 
parents of each participant are related to each other through their ancestors, was 
estimated using the PEDIG software,23 based on the pedigree of the total popula-
tion. PEDIG yields a coefficient for each participant, which was then entered as a 
covariate in the calculation of the heritability and genetic correlations. Sibship effects 
denote the exposure to early environmental factors that are shared by children of the 
same household. In this study, sibship effect estimates were phenotypic similarities 
induced in the progeny of the same mother because of the small number of half-sibs 
in our sample. This effect is a combination of effects induced by shared early life 
environment and dominance genetic effects. 
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Finally, to investigate the extent to which neuroticism and intelligence were interme-
diate factors in the causal pathway between the shared genetic factors and the co-
occurrence of symptoms of depression and lower socioeconomic status, the analyses 
were additionally adjusted for NEO-FFI neuroticism scores and DART premorbid 
intelligence scores. In this analysis we assume that if neuroticism and intelligence 
are intermediate factors in the pathway, (genetic) correlations will disappear when 
adjusting for these factors. SOLAR 2.1.2 software package (Southwest Foundation 
for Biomedical Research, San Antonio, Texas, USA) was used for the calculation of 
heritability estimates and for the genetic and environmental correlations. P values 
lower than 0.05 (two-tailed) were considered statistically significant.
Results
Of the 3,092 participants of the ERF Study, data on 2,383 were available for our 
analyses. Mean age of the participants was 48.7 years (SD 15.1) and 56.9% were 
women. Women reported more symptoms of depression on the CES-D scale and had 
higher NEO-FFI neuroticism scores (Table 1). Nine percent of the women reported 
the use of antidepressants compared to 4.3% of the men (p < 0.001). Higher levels 
of education were associated with lower scores on the CES-D (ρ=-0.09, p<0.001) 
and HADS-D (ρ=-0.17, p<0.001; Table 2) scales. Higher DART premorbid intelli-
gence scores were significantly correlated with higher levels of education (ρ=-0.48, 
p<0.001), and higher NEO-FFI neuroticism scores were significantly associated with 
higher scores on both scales of symptoms of depression scales (CES-D ρ=-0.51, 
p<0.001; HADS-D ρ=-0.50, p<0.001).
 Heritability estimates were 0.24 and 0.22 for the CES-D and HADS-D scores, 
0.36 for education level, 0.54 for DART premorbid intelligence scores and 0.28 for 
NEO-FFI neuroticism scores. The heritability estimate of education decreased to 0.15 
(p<0.001) after adjusting for DART premorbid intelligence scores, and the heritability 
estimates of CES-D and HADS-D depression scores decreased after adjusting for 
neuroticism (CES-D to 0.11 (p<0.001) and HADS-D to 0.12 (p<0.001). 
 Significant negative genetic correlations were found between education and both 
symptoms of depression scales (CES-D: ρG=-0.65, p<0.001; HADS-D: ρG=-0.50; 
p<0.001; Table 3). Genetic correlations between symptoms of depression and both 
DART premorbid intelligence scores and NEO-FFI neuroticism scores were statisti-
cally significant. The genetic correlations between education and symptoms of 
depression scores remained unchanged and statistically significant after additional 
adjustment for DART premorbid intelligence and NEO-FFI neuroticism scores (data 
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not shown). The environmental correlation was statistically significant for the as-
sociation of education with CES-D scores (ρE=0.10, p=0.05) but not with HADS-D 
scores (ρE=0.01, p=0.89), and for the association of NEO-FFI neuroticism scores 
with CES-D and HADS-D scores (ρE=0.51, p<0.001 and ρE=0.42, p=0.001). 
Table 1 General characteristics of the study population
Men (n=1,028) Women (n=1,355) p-Value
Age, years 48.8 (14.7) 48.6 (15.3)  0.79
Education
Lower 34.1 30.5 <0.001
Intermediate 58.1 65.8
Higher  7.8  3.7
Symptoms of depression
CES-D score 9.1 (8.6) 11.9 (10.2) <0.001
HADS-D score 6.0 (4.1)  6.1 (4.5)  0.62
Use of antidepressant medication  4.3  9.0 <0.001
DART score 61.5 (19.4) 58.6 (19.2)  0.002
NEO-FFI neuroticism score 29.7 (7.6) 32.6 (8.0) <0.001
CES-D = Center for Epidemiologic Studies Depression Scale, HADS-D = Hospital Anxiety and Depression 
Scale - Depression subscale, DART = Dutch Adult Reading Test (premorbid intelligence), NEO-FFI = NEO 
Five Factor Inventory.
Values are means (standard deviations) for continuous variables and percentages for categorical variables. 
p-values were obtained using χ2-statistics for categorical variables and univariate analysis of variance for 
continuous variables.
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Table 2 Phenotypic correlations between the study variables 
CES-D HADS-D Education DART score
Education -0.09*** -0.17***
Education, adjusted for DART score -0.06** -0.10**
Education, adjusted for neuroticism -0.02 -0.12***
DART premorbid intelligence -0.07** -0.16***  0.49***
NEO-FFI neuroticism  0.51***  0.51*** -0.15*** -0.15***
CES-D = Center for Epidemiologic Studies Depression Scale, HADS-D = Hospital Anxiety and Depression 
Scale - Depression subscale, DART = Dutch Adult Reading Test (premorbid intelligence), NEO-FFI = NEO 
Five Factor Inventory. Adjusted for age, sex, degree of consanguinity and use of antidepressant medication.
*p<0.05, **p<0.01, ***p<0.001
Table 3 Genetic and environmental correlations between symptoms of depression and educa-
tion, intelligence and neuroticism
CES-D HADS-D
ρG ρE ρG ρE
Education -0.65 (0.14)*** 0.10 (0.05)* -0.50 (0.13)*** 0.01 (0.05)
DART premorbid intelligence -0.31 (0.11)*** 0.04 (0.06) -0.45 (0.11)*** 0.04 (0.06)
NEO-FFI neuroticism  0.88 (0.06)*** 0.51 (0.03)***  0.77 (0.10)*** 0.42 (0.04)***
CES-D = Center for Epidemiologic Studies Depression Scale, HADS-D = Hospital Anxiety and Depression 
Scale - Depression subscale, DART = Dutch Adult Reading Test, NEO-FFI = NEO Five Factor Inventory. ρG 
= genetic correlation, ρE = environmental correlation.
Analyses are adjusted for age, sex, use of antidepressant medication, degree of consanguinity and sibship 
effects. Values are genetic correlations with standard errors.
*p<0.05, **p<0.01, ***p<0.001
Discussion
Our study demonstrates significant genetic correlations between symptoms of de-
pression and level of education, suggesting that shared genetic factors play a role in 
the clustering of depression among individuals with lower socioeconomic status. This 
genetic correlation most likely reflects shared causal pathways with genetic factors 
that play a role in both depression and socioeconomic status. We further showed 
that these shared genetic pathways did not involve neuroticism or intelligence, as the 
genetic correlations remained unchanged after adjusting for these personality traits.
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 Before interpreting the findings, two issues should be addressed. First, we used 
education as a proxy of socioeconomic status. Education is the most frequently used 
proxy, but this may be less appropriate in a three-generation study. Older partici-
pants with lower education levels may have acquired higher socioeconomic status 
by their work history, whereas younger participants did not have this opportunity 
yet. Hence, education level may be a less suitable proxy for socioeconomic status 
in older participants. Second, we observed slight differences in the results obtained 
for the CES-D and the HADS-D scores. While both scales are validated for the as-
sessment of symptoms of depression,18 the scales differ in the items included and 
may therefore lead to different results. Note that while the estimates of the genetic 
correlations differed in magnitude, the overall pattern of association was the same 
for the CES-D and the HADS-D scales. 
 The heritability estimates for both symptoms of depression and socioeconomic 
status in our population were in line with previously published studies.11-15 However, 
the variation in heritability estimates is large due to the differences between study 
populations, study design and methodology.24 The heritability estimates in our large 
extended family population were lower than in twin studies, and studies in smaller 
nuclear families generally give higher estimates. This is expected as in the latter 
studies the environmental and genetic background is more homogeneous, while in 
our study the environment and genetic background is more heterogeneous because 
the study spans multiple generations.
 The negative genetic correlations between education level and CES-D and 
HADS-D suggest that the same underlying genetic factors lead to more symptoms of 
depression and lower socioeconomic status. We investigated whether intelligence or 
neuroticism were intermediate factors in this genetic pathway, but found no evidence 
for this hypothesis. Genetic factors that predispose to intelligence do contribute to 
the heritability of education, and predisposing genes for neuroticism contribute to 
the heritability of depression, but they do not explain the co-occurrence of symp-
toms of depression and lower socioeconomic status. To date, only a few studies 
have assessed the association between socioeconomic status and genetic variants. 
Candidate genes which have been studied for both depression and socioeconomic 
status are the DRD4 gene and the APOE gene.25-28 However, for socioeconomic 
status no clear evidence has been established as the findings of genetic association 
studies have not yet been reproduced.
 Improving health through the reduction of socioeconomic inequalities has been 
a public health goal for decades.2 Depression is among other disorders such as 
cardiovascular disease, an outcome consistently associated to lower socioeconomic 
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status.2 Our results show that the co-occurrence may be partly explained by shared 
genetic factors. However, this does not mean that we cannot prevent depression 
among individuals with lower socioeconomic status by improving the environmental 
context. Most likely the depression is the consequence of a complex interaction 
between genes and environment. Developing programs to promote educational 
achievement and coping with life stresses in genetically vulnerable people will be 
crucial.
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shareD Genetic factors in the 
co-occurrence of symptoms of Depression 
anD carDiovascular risk factors
Abstract 
Objectives: We aim to investigate the extent to which shared genetic factors play a 
role in the co-occurrence of symptoms of depression and cardiovascular risk factors. 
Methods: The analyses included 2,383 individuals from a genetically isolated popula-
tion in the Netherlands. Symptoms of depression were assessed using the Center for 
Epidemiology Studies Depression Scale (CES-D) and the Depression subscale of the 
Hospital Anxiety and Depression Scale (HADS-D). Assessment of cardiovascular risk 
factors included systolic and diastolic blood pressure, plasma, glucose levels, high 
and low density lipoprotein (HDL, LDL) and total cholesterol levels. The degree of 
shared genetic and shared environmental factors in the co-occurrence of traits was 
quantified by estimating genetic and environmental correlations. Results: Overall, 
we found that HADS-D scores were significantly associated to total cholesterol levels 
(ρ=0.05; p=0.05), and inversely associated to HDL (ρ=-0.06; p=0.03). Significant 
genetic correlations were found between CES-D scores and total plasma choles-
terol (ρG=0.30, p=0.02), LDL (ρG=0.31, p=0.02) and total cholesterol/HDL ratios 
(ρG=0.25, p=0.04). For HADS-D scores, a significant genetic correlation was found 
with total cholesterol/HDL ratios (ρG=0.27, p=0.02). Environmental correlations 
with an opposite direction were found between CES-D and both total cholesterol 
(ρE=-0.16, p<0.001) and LDL (ρE=-0.15, p<0.001). Conclusions: Our study shows 
that from the cardiovascular risk factors studied, there is evidence for shared genetic 
factors contributing to the co-occurrence of symptoms of depression and lipid levels. 
This finding suggests a joint genetic pathogenesis.
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Introduction
Depression and cardiovascular disease (CVD) are two of the most common disorders 
in developed countries.1 According to the World Health Organization estimates, 
29% percent of all deaths globally are attributed to CVD each year, and depres-
sive disorders are the most frequently occurring psychiatric disease with a life-time 
incidence of around 25%.2 The prevalence of depression in patients with CVD is 
estimated at 20% to 35%.2,3 The causal mechanism behind this association is mul-
tidirectional, in that depression may lead to CVD, it may worsen CVD symptoms or 
it may result from CVD.4 
 In recent years, there has been an increasing interest in the hypothesis that 
depression and CVD risk factors may share common genetic pathways. Both de-
pression and CVD are partly determined by genetic predisposition. For both traits 
there is substantial evidence for a strong genetic component.5-9 The hypothesis of a 
joint genetic etiology is supported by genetic association studies that show associa-
tion of the angiotensin I converting enzyme (ACE) gene, methylenetetrahydrofolate 
reductase (MTHFR) gene, tyrosine hydroxylase (TH) gene, dopamine receptor D4 
(DRD4) gene, G-protein B3 subunit (GNB3) gene, and the serotonin transporter 
(SLC6A4) gene to depression and to CVD and its major risk factors such as hyperten-
sion and lipid levels.10-14 
 Apart from these candidate gene studies, there has been limited research on the 
role of shared genetic pathways in the association between depression and CVD. 
Only one study has investigated, the genetic correlation between depression and 
CVD risk factors.15 This study, among male twins from the Vietnam Era Twin Regis-
try, showed a significant genetic correlation between symptoms of depression and 
hypertension and heart disease.15 The aim of our study was to investigate the extent 
to which shared genetic factors explain the association between depression and 
CVD risk factors in a large family-based study. 
Subjects and methods
Subjects 
Subjects were participants of the Erasmus Rucphen Family (ERF) Study, a family-
based study that investigates the genetic origin of complex diseases in a genetically 
isolated community in the Southwest of the Netherlands. The study population es-
sentially consists of one extended family of descendants from 20 related couples that 
lived in the isolate between 1850 and 1900. All descendants were ascertained and 
descendants of 18 years and older were invited to participate. Spouses were invited 
only for family members that had children of 18 years and older. 
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Procedures 
All participants filled out questionnaires and underwent extensive medical examina-
tions. These examinations were conducted by physicians of the academic centers 
according to a standardized research protocol. The questionnaires addressed symp-
toms of depression, among other variables. The medical exam included the assess-
ment of medical history, medication use and blood pressure measurements. Fasting 
blood samples were drawn in order to measure lipid and glucose levels according 
to standardized procedures.16,17 Data were collected between 2002 and 2005. The 
study was approved by the Medical Ethical Committee of the Erasmus University 
Medical Center Rotterdam and all participants gave informed consent. 
Measurements
Symptoms of depression were assessed using the Center for Epidemiology Studies 
Depression Scale (CES-D),18 and the Depression subscale of the Hospital Anxiety 
Depression Scale (HADS-D).19 Both scales are validated and reliable self-report 
measures of symptoms of depression.18,19 The CES-D consists of 20 items with total 
scores ranging from 0 to 60 and the HADS-D consists of 7 items with scores ranging 
from 0 to 21. Higher scores indicate more symptoms of depression.
 CVD risk factors included blood pressure, glucose level and lipid levels. Blood 
pressure was measured twice on the right upper arm with the subject in a sitting 
position. Glucose and lipid levels (total cholesterol, high and low density lipoprotein 
levels (HDL, LDL)) blood chemistry were analysed on a spectrophotometric chemis-
try analyser (Synchron LX20; Beckman, Fullerton, California, USA). 
Statistical analysis 
General characteristics were compared between men and women and tested using 
ANOVA for continuous variables and chi-squared test for dichotomous variables. To 
quantify the strength of the phenotypic association between symptoms of depression 
and cardiovascular risk factors, partial correlations (ρ) were calculated adjusting for 
age, sex, degree of consanguinity and the use of antidepressant medication. Multiple 
linear regression models were fitted to assess the distributional assumption of nor-
mality. Systolic and diastolic blood pressure, plasma glucose levels, HDL, LDL and 
total cholesterol levels were natural log-transformed to ensure normally distributed 
residuals. The normality of residuals was tested using a one-sample Kolmogorov-
Smirnov test. These analyses were performed using SPSS 11.0 for Windows.
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Heritability estimates (h2) were calculated as the ratio of the variance of the trait 
explained by additive polygenic effects to the total phenotypic variance of the 
trait. Bivariate analyses were performed to estimate the genetic and environmental 
correlations between the depression scores and CVD risk factors. The genetic and 
environmental correlations can be calculated from the phenotypic correlations (ρP) 
by the following formula: ρP = [square root]h12[square root]h22ρG + [square root]
(1-h1
2)[square root](1-h2
2)ρE,22, 23 where h12 and h22 are the heritability estimates of 
the traits, for which the phenotypic correlation is calculated, and ρG and ρE are the 
genetic and environmental correlations between these two traits. Significance of the 
additive genetic and environmental correlations was determined using a likelihood 
ratio test. To test whether a given correlation between two traits was significantly dif-
ferent from zero, the likelihood of a model in which this correlation was constrained 
to zero was compared with a model in which the same correlation was estimated. 
Twice the difference in ln-likelihoods of these models yields a test statistic that is 
asymptotically distributed as a chi-squared statistic with degrees of freedom equal to 
the difference in number of parameters estimated in the two models. 
 Analyses were adjusted for age, sex, use of medication, degree of consanguinity 
and sibship effects. The degree of consanguinity, indicating the degree to which 
parents of each participant are related to each other through their ancestors, was 
estimated using the PEDIG software,24 based on the pedigree of the total popula-
tion. PEDIG yields a coefficient for each participant, which was then entered as a 
covariate in the calculation of the heritability and genetic correlations. Sibship effects 
denote the exposure to early environmental factors that are shared by children of the 
same household. In this study, sibship effect estimates were phenotypic similarities 
induced in the progeny of the same mother because of the small number of half-
sibs in our sample. This effect is a combination of effects induced by shared early 
life environment and dominance genetic effects. SOLAR 2.1.2 software package 
(Southwest Foundation for Biomedical Research, San Antonio, Texas, USA) was used 
for the calculation of heritability estimates and for the genetic and environmental 
correlations. P values lower than 0.05 (two-tailed) were considered statistically sig-
nificant.
Results
The study included 2,383 participants, 1,355 women and 1,028 men. Women 
reported more symptoms of depression and more frequently used antidepressive 
medication (Table 1). Men had worse cardiovascular profiles with significantly higher 
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systolic and diastolic blood pressure, higher glucose levels, higher total cholesterol 
levels and lower HDL levels. Furthermore, men more frequently used antihyperten-
sive medication and lipid modifying agents. Table 2 shows that there was a moderate 
correlation between the CES-D and HADS-D depression scores and between the 
cardiovascular risk factors. HADS-D was significantly associated to total choles-
terol/HDL ratio levels (ρ=0.05; p=0.05) and inversely associated to HDL (ρ=-0.06; 
p=0.03). 
Table 1 General characteristics of the study population
Men (n=1,028) Women (n=1,355) p-Value
Age, years  48.8 (14.7)  48.6 (15.3)  0.79
Symptoms of depression
CES-D score   9.1 (8.6)  11.9 (10.2) <0.001
HAD-D score   6.0 (4.1)   6.1 (4.5)  0.62
Cardiovascular risk factors
Systolic blood pressure (mm Hg) 142.7 (17.6) 136.4 (21.0) <0.001
Diastolic blood pressure (mm Hg)  81.6 (9.6)  78.7 (9.8) <0.001
Glucose (mmol/l)   4.7 (1.1)   4.4 (0.8) <0.001
Total cholesterol (mmol/l)   5.5 (1.1)   5.6 (1.1)  0.01
High density lipoprotein (mmol/l)   1.1 (0.3)   1.4 (0.4) <0.001
Total cholesterol/HDL ratio   5.1 (1.5)   4.2 (1.2) <0.001
Low density lipoprotein (mmol/l)   3.8 (1.0)   3.7 (1.0)  0.54
Medication use
Antidepressants   4.3   9.0 <0.001
Antihypertensives  37.3  28.7  0.001
Insulin   4.3   2.6  0.06
Lipid modifying agents  26.2  16.3 <0.001
CES-D = Center for Epidemiologic Studies Depression Scale, HADS-D = Hospital Anxiety and Depression 
Scale. Values are means (standard deviations) for continuous variables and percentages for categorical 
variables. p-values were obtained using univariate analysis of variance for continuous variables and χ2-
statistics for categorical variables.
T
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Table 3 Heritability estimates of depression and cardiovascular risk factors
H2 (se)
HADS-D 0.24 (0.04)
CES-D 0.22 (0.04)
Systolic blood pressure (mmHg) 0.18 (0.05)
Diastolic blood pressure (mmHg) 0.29 (0.04)
Glucose (mmol/l) 0.23 (0.05)
Cholesterol (mmol/l) 0.26 (0.05)
High density lipoprotein (mmol/l) 0.46 (0.05)
Total cholesterol/HDL ratio 0.36 (0.05)
Low density lipoprotein (mmol/l) 0.28 (0.05)
All p-values <0.001, se = standard error.
 Adjusted for age, sex, degree of consanguinity and use of antidepressant medication
Table 4 Genetic and environmental correlation between symptoms of depression and cardio-
vascular risk factors
 CES-D HADS-D
 ρG ρE ρG ρE
Systolic blood pressure (mmHg) -0.15 (0.16) -0.03 (0.05)  0.11 (0.18) -0.07 (0.04)
Diastolic blood pressure (mmHg)  0.008 (0.12) -0.04 (0.04)  0.15 (0.13) -0.08 (0.04)
Glucose (mmol/l)  0.12 (0.14) -0.05 (0.05)  0.24 (0.17) -0.03 (0.04)
Cholesterol (mmol/l)  0.30 (0.13)* -0.16 (0.05)***  0.21 (0.15) -0.07 (0.05)
High density lipoprotein (mmol/l) -0.10 (0.11) -0.03 (0.05) -0.20 (0.11) -0.003 (0.05)
Total cholesterol/HDL ratio  0.25 (0.12)* -0.06 (0.05)  0.27 (0.12)* -0.02 (0.05)
Low density lipoprotein (mmol/l)  0.31 (0.13)* -0.15 (0.05)***  0.20 (0.14) -0.05 (0.05)
CES-D = Center for Epidemiologic Studies Depression Scale, HADS-D = Hospital Anxiety and Depression 
Scale, HDL = high-density lipoprotein. ρG = genetic correlation, ρE = environmental correlation. 
Values between brackets are standard errors. Analyses are adjusted for age, sex, use of medication (anti-
depressants, antihypertensives, insulin and lipid modifying agents), degree of consanguinity and sibship 
effects. 
*p<0.05, **p<0.01, ***p<0.001
Heritability estimates were 0.24 (p<0.001) for CES-D and 0.22 (p<0.001) for HADS-
D scores (Table 3). Heritability estimates for CVD risk factors ranged from 0.18 
(p<0.001) for systolic blood pressure to 0.46 (p<0.001) for HDL levels. Table 4 pres-
ents the genetic and environmental correlations between symptoms of depression 
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and CVD risk factors. Significant genetic correlations were found for CES-D scores 
with total cholesterol (ρG=0.30; p=0.02) and LDL levels (ρG=0.31; p=0.02) and 
for both CESD-D and HADS-D scores with total cholesterol/HDL ratios (ρG=0.25; 
p=0.04 and ρG=0.27; p=0.02) respectively. No evidence for a genetic correlation was 
found for glucose or blood pressure to either HADS-D or CES-D scores. Statistically 
significant environmental correlations in the opposite direction were found between 
CES-D scores and both total cholesterol (ρE=-0.16) and LDL levels (ρE=-0.15).
Discussion
We investigated genetic correlations between symptoms of depression and CVD 
risk factors and found significant genetic correlations of CES-D scores with total 
cholesterol, LDL and total cholesterol/HDL ratios and of HADS-D scores with total 
cholesterol/HDL ratios. Furthermore, we observed statistically significant negative 
environmental correlations of CES-D scores with total cholesterol and LDL.
 The only study to date that has assessed the genetic relationship between vas-
cular risk factors and depression found an association between hypertension and 
symptoms of depression.15 We did not find any correlation between blood pressure 
and symptoms of depression in the overall group, or when analyzing men only.
 There is strong support for the hypothesis that abnormal lipid and related fatty 
acid metabolism contributes to depression.25 The enzymes, and other proteins that 
regulate the phospholipid metabolism, are for a large part genetically determined and 
clearly of interest in relation to depression and symptoms of depression. A review 
listed more than 100 candidate genes encoding for proteins involved in the me-
tabolism of phospholipids and fatty acids which are localized in regions previously 
associated to psychiatric disorders.26 To date the apolipoprotein E gene has been 
associated to depression,14 and the prostaglandin and lipoprotein lipase genes have 
been related to bipolar disorder.26 To what extend other lipids are involved remains 
to be determined. 
 Of note is that the environmental correlations between the CES-D scores and 
CVD risk factors showed an inverse relation. While shared genetic factors contribute 
to the co-occurrence of symptoms of depression and higher plasma total choles-
terol and higher plasma LDL levels, shared environmental factors contributed to the 
co-occurrence of depression and lower plasma total cholesterol, and lower plasma 
LDL levels. When comparing the genetic and environmental correlations, genetic 
correlations were higher resulting in an overall positive correlation when ignor-
ing the genetic or environmental origin of the correlation. The significant inverse 
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environmental correlation may be related to the fact that (extremely) low cholesterol 
levels have been related to a higher prevalence of symptoms of depression and sui-
cide.25 Although there may be biological explanations for this inverse relationship, 
alternatively one may hypothesize that the low lipid levels result from dietary habits 
or medication that are a consequence of symptoms of depression. 
 In conclusion, we found evidence for a shared genetic origin of the co-occurrence 
of symptoms of depression and blood lipid levels as well as for a shared environmen-
tal factor explaining the opposite direction. These findings are compatible with the 
view of a shared genetic origin of symptoms of depression and blood lipid levels, or, 
alternatively of symptoms of depression and brain lipid levels.
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Abstract 
Objective: Both obesity and lean mass have been correlated with symptoms of 
depression. We aimed to investigate the contribution of genetic and environmental 
factors in the co-occurrence of these traits, and examined the role of personality 
and education in the shared etiological pathways. Methods: Subjects were 2,383 
participants of the Erasmus Rucphen Family (ERF) Study. Symptoms of depression 
were assessed using the Center for Epidemiologic Studies Depression Scale (CES-D) 
and the Hospital Anxiety and Depression Scale (HADS-D). The NEO-Five Factor 
Inventory was used to assess personality traits. Anthropometric and Dual Energy 
X-ray Absorptiometry (DEXA) total body scans were obtained for the assessment of 
body composition. The role of shared genetic and shared environmental factors was 
quantified by estimating genetic (ρG) and environmental (ρE) correlations between 
symptoms of depression and measures of body composition, with and without ad-
justment for personality traits, education and sibship effects. Results: Phenotypic 
correlations between body composition and symptoms of depression ranged from 
-0.08 to 0.08. Heritability estimates for body composition ranged from 0.40 to 0.46 
(p<0.001) in women and from 0.35 to 0.51 (p<0.001) in men, and heritability esti-
mates for depression scores were higher in women (0.34 and 0.37) than in men (0.13 
and 0.21). No consistent genetic correlations between measures of body composition 
and symptoms of depression were found. We did find a significant consistent envi-
ronmental correlation between depression scores and lean mass index (ρE = -0.23 
for CES-D and -0.31 for HADS-D). These correlations did not change after additional 
adjustment for education and personality. Conclusions: In our study, there is no 
evidence that the co-occurrence of symptoms of depression and body composition 
result from a common genetic pathway. 
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Introduction
Both obesity and lean mass have been correlated with symptoms of depression. 
Symptoms of depression and obesity frequently co-occur,1-3 while an inverse rela-
tionship between lean mass and depression is seen.4 There are multiple explanations 
for the clustering of obesity and depression traits, in either direction.5,6 First, obese 
persons may be more likely to become depressed due to psychosocial and behav-
ioral implications of obesity, such as lack of self-confidence, isolation and inactivity.1 
Second, depressed persons may be more likely to develop obesity due to physiologic 
mechanisms such as overeating and physical inactivity.1 And third, obesity and de-
pression may result from the same underlying causes, such as education, personality, 
disturbances of the hypothalamic-pituitary-adrenal axis and serotonin/dopamine 
pathways, which are known to play major roles in both traits.7-13 Evidence for com-
mon etiological pathways is supported by the results of genetic association studies, 
which have shown that several genes such as the glucocorticoid receptor gene,14,15 
the corticotrophin releasing hormone receptor gene,16,17 the serotonin 2A and 2C 
receptor gene,18-21 and the dopamine receptor D4 gene,22,23 have been associated 
to both obesity and depression. Also the causal mechanism for the relationship 
between lean mass and depression may be multidirectional. Indeed, determinants 
of lean mass such as physical activity may be also associated to depression, but it 
can also be argued that depression leads to inactivity and a reduction in lean mass. 
Regarding the latter hypothesis, there is increasing interest in the role of physical 
activity in the treatment of depression.24
 Obesity, lean mass and depression are both substantially caused by genetic de-
terminants.25-27 Heritability estimates, indicating the proportion of variance of a trait 
that is explained by additive genetic factors, vary widely for obesity related factors, 
ranging from 50% to 70% for body mass index (BMI),25,26 36% to 61% for waist-to-
hip ratio (WHR), 72% to 82% for waist circumference,28 and 60% to 79% for lean 
mass.29,30 Heritability estimates for depression range from 17% to 78%.27 Given the 
high heritability, and their co-occurrence, one may hypothesize that genetic factors 
underlie the clustering of these traits. The aim of this study was to investigate the 
extent to which shared genetic and shared environmental factors contribute to the 
co-occurrence of symptoms of depression with fat and muscle mass. 
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Subjects and methods
Subjects 
Subjects were participants of the Erasmus Rucphen Family (ERF) Study, a family-
based study that investigates the genetic origins of complex diseases in a genetically 
isolated community in the Southwest of the Netherlands. The study population es-
sentially consists of one extended family of descendants from 20 related couples that 
lived in the isolate between 1850 and 1900. All descendants were ascertained and 
descendants of 18 years and older were invited to participate. Spouses were invited 
only for family members that had children of 18 years and older. 
Procedures 
All participants filled out questionnaires and underwent extensive medical examina-
tions. These examinations were done by research physicians of the academic center 
according to a standardized protocol. The questionnaires addressed education level, 
symptoms of depression, and personality, and the medical exam included assess-
ment of medical history, antidepressant use, anthropometrics and body composition. 
Data were collected between 2002 and 2005. The study was approved by the Medi-
cal Ethical Committee of the Erasmus University Medical Center Rotterdam and all 
participants gave informed consent. 
Measurements
Measures of body composition were obtained from anthropometric assessments, 
which included height, weight, waist and hip circumference, and a Dual Energy 
X-ray Absorptiometry (DEXA) total body scan. Waist circumference was measured 
midway between the lower costal margin and the iliac crest, and hip circumference 
at the widest diameter of the hip. Waist to hip ratio (WHR) was computed as the 
waist circumference divided by the hip circumference. Body Mass Index (BMI) was 
computed as weight in kilograms divided by the squared height in meters. DEXA 
scans were performed in a calibrated Prodigy total body fanbeam densitometer 
and analyzed with enCORE 2002 software version 6.70.021 (GE Lunar, Madison, 
WI, USA). DEXA measurements were used to calculate the fat mass and lean mass 
indices, which respectively are the total fat mass and lean mass in kilograms divided 
by the squared height in meters, similar to how we calculated BMI.
 Symptoms of depression were assessed using the Center for Epidemiologic 
Studies Depression Scale (CES-D),31 and the depression subscale of the Hospital 
Anxiety Depression Scale (HADS-D).32 Both the CES-D and HADS-D are validated 
and reliable self-report measures of symptoms of depression.33 The CES-D consists 
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of 20 items with total scores ranging from 0 to 60, and the HADS-D consists of 7 
items with scores ranging from 0 to 21. Higher scores indicate more symptoms of 
depression.
 Personality was assessed using the NEO five factor inventory (NEO-FFI), measur-
ing five major domains of personality, including neuroticism, extraversion, openness 
to experience, agreeableness and conscientiousness.34 The NEO-FFI is a self-report 
questionnaire consisting of 60 statements answered on a five-point Likert scale with 
domain scores ranging from 0 to 48 each. 
Statistical analysis
General characteristics were compared between men and women and tested using 
ANOVA for continuous variables and chi-squared test for dichotomous variables. To 
quantify the strength of the phenotypic association between symptoms of depression 
and measures of body composition, partial correlations (ρ) were calculated adjust-
ing for age, sex, degree of consanguinity and the use of antidepressant medication. 
Individuals with a BMI lower than 18.5 kg/m² were excluded from the main analyses. 
Multiple linear regression models were fitted to assess the distributional assumption 
of normality. The normality of residuals was tested using a one-sample Kolmogorov-
Smirnov test. These analyses were performed using SPSS 11.0 for Windows.
 Heritability estimates (h2) were calculated as the ratio of the variance of the trait 
explained by additive polygenic effects to the total phenotypic variance of the trait. 
Bivariate analyses were performed to estimate the genetic and environmental cor-
relations between the depression scores and measures of body composition. The 
genetic and environmental correlations were calculated from the phenotypic cor-
relations (ρP) by the following formula: ρP = [square root]h12 [square root]h22ρG + 
[square root](1-h1
2)[square root](1-h2
2)ρE, 35, 36 where h12 and h22 are the heritability 
estimates of the traits, for which the phenotypic correlation is calculated, and ρG and 
ρE are the genetic and environmental correlations between these two traits. Signifi-
cance of the additive genetic and environmental correlations was determined using 
a likelihood ratio test. To test whether a given correlation between two traits was 
significantly different from zero, the likelihood of a model in which this correlation 
was constrained to zero was compared with a model in which the same correlation 
was estimated. Twice the difference in ln-likelihoods of these models yields a test 
statistic that is asymptotically distributed as a chi-squared statistic with degrees of 
freedom equal to the difference in the number of parameters estimated in the two 
models. 
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Analyses were adjusted for age, sex, use of medication, degree of consanguinity 
and sibship effects. The degree of consanguinity, indicating the degree to which 
parents of each participant are related to each other through their ancestors, was 
estimated using the PEDIG software,37 based on the pedigree of the total popula-
tion. PEDIG yields a coefficient for each participant, which was then entered as a 
covariate in the calculation of the heritability and genetic correlations. Sibship effects 
denote the exposure to early environmental factors that are shared by children of the 
same household. In this study, sibship effect estimates were phenotypic similarities 
induced in the progeny of the same mother because of the small number of half-sibs 
in our sample. This effect is a combination of effects induced by shared early life 
environment and dominance genetic effects. 
 Finally, to investigate the extent to which education and personality were inter-
mediate factors in the causal pathway between the shared genetic factors and the 
co-occurrence of body composition and symptoms of depression, analyses were 
additionally adjusted for education and personality in separate models. SOLAR 2.1.2 
software package (Southwest Foundation for Biomedical Research, San Antonio, 
Texas, USA) was used for the calculation of heritability estimates and for the genetic 
and environmental correlations. P values lower than 0.05 (two-tailed) were consid-
ered statistically significant.
Results
Of the 3,092 participants of the study, data on 2,383 were available for the outcomes 
studied in the present analyses. Mean age of the participants was 48.7 years (SD 15.1) 
and 56.9% were women. A total of 55.6% of the women and 70.5% of the men were 
overweight or obese (Table 1; p<0.001). Women had significantly higher fat mass 
index, higher CES-D depression scores and more frequently used antidepressants. 
Men had higher lean mass index and more abdominal obesity. 
 In women and men, a higher waist to hip ratio was correlated to a significantly 
higher level of symptoms of depression as measured with the HADS-D but not with 
the CESD-D scores (Table 2). In men, a consistently significant inverse correlation 
was seen between the lean mass index and the CES-D and HADS-D scores and also 
a higher BMI was correlated to a significantly lower level of symptoms of depression 
as measured with the CESD-D but not with the HADS-D scores. When studying 
the correlation between body composition and depression with the putative con-
founders education and personality (Table 3), we found that education was inversely 
association to CES-D (p<0.001), HADS-D scores (p<0.001) and to waist to hip ratio 
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(p<0.001). Symptoms of depression were associated with all NEO-FFI personality 
types (Table 3), and there were only scattered correlations with body composition 
measures. Extraversion was significantly correlated to lean mass index, conscien-
tiousness was significantly inversely correlated to fat mass index and neuroticism and 
openness were correlated to the waist to hip ratio in opposite directions.
Table 1 General characteristics of the study population
Women (n=1,355) Men (n=1,028) p-Value
Age, years 48.6 (15.3) 48.8 (14.7)  0.79
Body mass index, kg/m² 26.4 (4.9) 27.2 (4.3) <0.001
Underweight (<18.5)  1.2  0.7
Normal weight (18.5 – 24.9) 43.2 28.8
Overweight (25.0 – 29.9) 35.7 49.3
Obese (> 30.0) 19.9 21.2
Lean mass index, kg/m² 15.2 (1.6) 19.0 (2.0) <0.001
Fat mass index, kg/m² 10.1 (3.7)  7.3 (2.9) <0.001
Waist to hip ratio  0.80 (0.08)  0.94 (0.08) <0.001
Abdominal obesity† 12.0 22.1 <0.001
Symptoms of depression
CES-D 11.9 (10.2)  9.1 (8.6) <0.001
HADS-D  6.1 (4.5)  6.0 (4.1)  0.62
Use of antidepressant medication  9.0  4.3 <0.001
Education level
Lower 30.5 34.1 <0.001
Intermediate 65.8 58.1
Higher  3.7  7.8
Personality type (NEO-FFI) 
Neuroticism 32.6 (8.0) 29.7 (7.6) <0.001
Extraversion 39.7 (6.5) 40.3 (6.5)  0.05
Openness 33.5 (5.9) 33.1 (5.5)  0.21
Agreeableness 45.0 (5.4) 42.0 (5.4) <0.001
Conscientiousness 46.3 (5.9) 46.5 (5.8)  0.62
CES-D = Center for Epidemiologic Studies Depression Scale, HADS-D = Hospital Anxiety and Depression 
Scale-Depression subscale, NEO-FFI = NEO five factor inventory.
Values are means (standard deviations) for continuous variables and percentages for categorical variables. 
† Abdominal obesity = Percentage of individuals with waist to hip ratio ≥0.9 in men and ≥1.0 in women.
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Table 2 Correlations of body composition with symptoms of depression by sex
CES-D HAD-D
Women Men Women Men
Body mass index -0.01 0.02 -0.07* -0.03
Lean mass index -0.01 0.02 -0.08* -0.08*
Fat mass index -0.02 0.02 -0.05  0.01
Waist to hip ratio 0.05 0.08* -0.01 0.08*
CES-D = Center for Epidemiologic Studies Depression Scale
HAD-D = Hospital Anxiety and Depression Scale –Depression subscale
Adjusted for antidepressant use
*p<0.05
  Table 4 shows that for both depression scales, heritability estimates were higher 
in women (0.34 and 0.37) than in men (0.13 and 0.21). Heritability estimates for 
body composition ranged from 0.40 to 0.46 (p<0.001) in women and from 0.35 to 
0.51 (p<0.001) in men (Table 3). There were statistically significant sibship effects for 
all measures of body composition in women (c² = 0.11 to 0.20, 0.05<p<0.001), but 
not in men (Table 4).
 When decomposing the phenotypic correlations into genetic and environment 
correlations, the positive correlation between waist-to-hip ratio and symptoms of 
depression did not remain statistically significant. There was no evidence for a role of 
shared genetic factors in the co-occurrence of body composition and symptoms of 
depression in men or women (Table 5). Genetic correlations were highest between 
the HADS-D depression scores and waist-to-hip ration in men, but these were not 
statistically significant. We found an effect of shared environmental factors in the 
relation of lean mass index with CES-D and HADS-D depression scores in men (ρE 
= -0.23 and -0.31, p<0.05), but not in women. Shared environmental factors also 
related higher body mass index to lower depression scores as measured with the 
HADS-D (ρE = -0.22, p<0.05). These correlations did not change after additional 
adjustment for education and personality in separate analyses (data not shown).
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Discussion
We found significant evidence for a relationship between body composition and 
symptoms of depression. In women and men, higher waist to hip ratio was corre-
lated to a significantly higher level of symptoms of depression as measured with the 
HADS-D. In men, a consistent significant inverse correlation was seen between the 
lean mass index and both the CES-D and HADS-D scores. In men, also a higher BMI 
was correlated to a significantly lower level of symptoms of depression as measured 
with the CESD-D scores. We found no evidence that the co-occurrence of the fat 
or lean mass related outcomes and symptoms of depression are explained by the 
same genetic factors. We did find a consistent and significant positive environmental 
correlation between lean mass index and symptoms of depression in men, suggest-
ing that both lean mass index and symptoms of depression are affected through 
the same environmental factors. An evident candidate for this shared pathway is 
physical activity, which increases lean mass index by acquiring more muscles, and 
decreases symptoms of depression by maintaining low base endorphin levels.38 Also 
body mass index showed a statistically significant inverse environmental correlation 
to HADS-D scores, but this may be a false positive finding as the association to the 
CES-D scores was not significant. An explanation for this finding may be that BMI 
measures both fat and lean mass and that the inverse association between BMI and 
HADS-D is explained by the inverse association of lean mass index to HADS-D.
 Before interpreting the results, two methodological issues need to be discussed. 
First, overall phenotypic correlations between body composition and symptoms of 
depression were low in our study. However, findings of other studies show similar 
correlations.39 When decomposing the correlation into genetic and environment 
correlations, the overall phenotypic positive correlation between waist to hip ratio 
and symptoms of depression did not remain statistically significant. Although we 
have studied a large data set, this finding could be explained by sheer lack of power. 
Second, we used two depression scales and found slight differences in the results 
obtained for the CES-D and the HADS-D scores. While both scales are validated for 
the assessment of symptoms of depression,33 the correlation between the depression 
scales was high (Pearson correlation coefficient=0.75, p<0.001) but not perfect. The 
scales may assess slightly different symptoms and may lead to differences in results. 
It is of note that while the estimates of the genetic correlations differed in magnitude, 
the overall pattern of association was the same for the CES-D and the HADS-D, 
except for the instances when the correlation for one scale or both scales was virtu-
ally zero. 
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Our study showed that the heritability estimates of body composition and depression 
were high, in particular in women. Of further interest is the consistent finding of 
significant sibship effects for body composition in women and not in men. This effect 
could be explained by dietary behaviors. Like in most traditional societies where 
women are responsible for the cooking, we may see a sibship effect in women when 
they have adopted the cooking and dietary habits from their mothers. An alterna-
tive explanation is that sibship effects reflect dominance variance, which cannot 
be excluded from the present analyses. An interesting finding is that symptoms of 
depression were significantly associated with education, which is a proxy measure 
for socioeconomic status.40 
 Our study did not show evidence for shared genetic factors influencing the co-
occurrence between obesity and depression nor the inverse relationship between 
lean mass and depression. This implies that in our study there is no evidence that 
symptoms of depression, fat mass, or lean mass are caused by the same underlying 
genetic pathways. Our findings did not change when we additionally adjusted for 
education and personality. Overall, we observed evidence for a phenotypic relation 
between symptoms of depression and waist to hip ratio, which is an important de-
terminant of metabolic syndrome. Our study does not answer the question whether 
this co-occurrence is explained by shared genetic or environmental pathways, as 
neither of these was significant. Although genetic factors may play a role in the 
co-occurrence of a high waist to hip ratio with symptoms of depression, they do 
not seem to dominate over the role of environmental ones. These findings do not 
exclude that genetic factors underlie obesity and that obesity consequently leads 
to depression, or alternatively that genetic factors underlie depression and that the 
depression consequently leads to obesity. 
 The most pronounced finding was the consistent and significant evidence for a 
role of shared environmental factors in the association between lean and fat mass 
index and symptoms of depression. It has been recognized for long that there is a 
relationship between lean mass and symptoms of depression. However, few studies 
addressed the relation of fat mass index and symptoms of depression. Lean mass has 
been more difficult to address, but the DEXA allowed us to disentangle to assess this 
outcome directly. 
 Elucidating the common etiology of obesity and depression is relevant for public 
health. If genetic factors underlie the clustering, different approaches are needed 
than is the case when environmental factors underlie the clustering. From a public 
health perspective the most important finding of our study is that co-occurrence 
of higher lean mass and less symptoms of depression is primarily of environmental 
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origin.38 There is increasing interest in the role of physical activity in the treatment 
of depression and our findings suggest that further research is justified.24 
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General Discussion
The aim of this genetic epidemiological thesis was to study candidate genes that 
play a role in the etiology of depression and to obtain new insights about biologi-
cal pathways that may be involved in this disorder. In this chapter, the findings of 
the study are reviewed and discussed, and topics for future research are addressed. 
Before discussing and interpreting the main findings, methodological issues with 
regard to the design of the study and the instruments used are reviewed. Advantages 
and disadvantages of the various approaches are discussed.
9
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Methodological issues
Definition and measurement of depression
As discussed in the introduction, depression can refer to the presence of symptoms 
of depression or to the clinical diagnosis of MDD. The presence of symptoms of 
depression is generally assessed using a self-report questionnaire designed for use in 
research or for primary care.1 MDD is diagnosed by a psychiatrist after an in-depth 
interview following the criteria of the DSM-IV. 1
 We chose to measure symptoms of depression instead of diagnosing MDD, and 
to analyze the sum scores of the self-report questionnaires as continuous variables 
for several reasons. The first reason is a practical reason, self-report questionnaires 
are easy to administer in large epidemiological studies. Second, including the de-
pression scores as a continuous variable, prevents misclassification of individuals 
with sub-clinical depression. When formal diagnostic criteria are applied, individuals 
with substantial symptoms of depression who do not fulfil the formal diagnostic 
criteria are commonly erroneously assigned to the control group.1 And third, analyz-
ing the depression scores as a continuous variable increases the statistical power 
considerably.2 There are also disadvantages of using self-report questionnaires for 
the assessment of symptoms of depression compared to using in-depth psychiatric 
interviews for MDD diagnosis. The subgroup that has high depression scores does 
not only include MDD patients, but a more heterogeneous group such as individuals 
with normal grief, bipolar disorder, anxiety, substance abuse, and dysphoria.3 This 
means that when localizing genes, we cannot explicitly assume that these are specifi-
cally involved in MDD as the clinical entity of interest but rather are predisposing to 
a more heterogeneous phenotype. This makes it difficult to target genes predisposing 
for a specific disorder such as MDD. Despite the obvious advantages of studying 
endophenotypes from a genetic perspective, from a clinical perspective MDD as an 
outcome may be more relevant for diagnostic, prognostic and therapeutic applica-
tions. However, in most cases, the two different methods of assessing depression can 
be complimentary to each other. When studying symptoms of depression we can 
maximize the statistical power, and increase our probability of finding susceptibility 
genes for depression. Once genes are localized, these can be subsequently studied 
in MDD patients to validate their role. 
Family-based versus population-based studies
This thesis describes results from a family-based and a population-based association 
study. The two approaches are complementary to each other and both have ad-
vantages and disadvantages. The family-based Erasmus Rucphen Family Study (ERF) 
was embedded in the Genetic Research in Isolated Populations (GRIP) programme, 
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which investigates the genetic origin of complex genetic disorders and traits. The ad-
vantage of the GRIP population is that the relationships between inhabitants are well 
documented. This allows research on the co-segregation of diseases over multiple 
generations to study the question whether the co-occurrence of depression with 
other disorders can be explained by a common genetic origin. Another opportunity 
is to conduct linkage studies of complex genetic traits, which aim at identifying rare 
genetic variants that have large effects on the risk of disease. Linkage studies have 
been conducted successfully in GRIP and other populations such as Iceland.4-6 
 Most of the genetic epidemiological studies performed to date are being con-
ducted in population-based studies. Population-based studies provide a powerful 
setting for candidate gene studies and for the recently introduced genome wide 
association studies. This new approach targets the discovery of common variants 
with small effects. Although the successes for genome wide association studies have 
been limited for depression, it has been extremely successful for a variety of complex 
traits such as diabetes, multiple sclerosis and breast cancer. By enlarging the study 
size of studies of MDD and other depressive disorders, the genome wide associa-
tion approach may lead to success for these disorders as well. Despite the fact that 
genome wide association studies are most powerful in population-based studies, 
they can and have been conducted successful in family-based studies such as the 
GRIP programme.
Meta-analysis
We reviewed all MDD case-control genetic association studies published before June 
2007 and performed meta-analyses for polymorphisms that had been investigated 
in at least three studies. With this method we were able to combine the results of 
many studies and increase statistical power. This is particularly important in studies 
of depression, as most studies have been performed in small samples.7 Two known 
methodological issues in meta-analyses are between-study heterogeneity and bias. 
Between-study heterogeneity may reflect real differences between study popula-
tions, but it may also be due to methodological differences between studies. True 
differences between study populations, for instance, can occur if study populations 
differ in age, sex or ethnicity of the participants. Because of the limited number of 
genetic association studies that have been performed on depression, we were not 
able to perform stratified analyses to study possible sources of heterogeneity in the 
several meta-analyses that showed substantial between-study heterogeneity. This 
implies that more replication studies are needed. Because several meta-analyses 
showed evidence for between-study heterogeneity, more studies are needed to 
investigate the causes of heterogeneity in more detail.
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The second methodological issue in meta-analyses is bias. There are three common 
biases in meta-analyses that should be considered when interpreting the results: (1) 
the winner’s curse or first study bias, (2) the large number of false positive findings 
in small studies, and (3) publication bias, which is related to the fact that journals 
are more likely to publish papers with positive findings.8,9 First, the winner’s curse 
predicts that often the first study published demonstrates a strong significant associa-
tion that is very extreme compared to the true effect and is therefore not replicated 
by subsequent studies. It is possible to identify this type of bias by removing the first 
study from the analysis. If the overall effect estimate (relative risk or odds ratio) shifts 
towards the null-hypothesis or becomes non-significant, it is likely that the initial 
positive finding is explained by this type of bias. Second, small studies tend to give 
not only false negative findings due to a lack of power, but also often give false posi-
tive findings, which are not replicated in larger studies. This makes it not only crucial 
to weigh for the study size in the meta-analysis, but also to examine the excess of 
positive findings, if sufficient studies are available. Finally, due to publication bias, 
studies with statistically significant findings are more likely overrepresented in the 
literature and therefore also in meta-analyses, biasing the findings to statistically sig-
nificant overall effects, which then more likely are false positive effects. Publication 
bias is generally examined using funnel plots,10 but this is one of the most difficult 
biases to exclude. Due to the limited number of genetic association studies that have 
been performed in depression, we were not always able to perform appropriate bias 
checks.
Studies on the co-occurrence of disease
Our study focused for a large part on the co-occurrence of depression with other 
traits. This is a unique analysis that can be performed in family- based studies. Yet 
these analyses also have their limitations. First, we distinguished genetic effects from 
shared early environment effects by adjusting the bivariate analyses for sibship ef-
fects. The advantage is that the heritability estimates then indicates a true genetic 
effect, but this may be an underestimation because sibship effects not only denote 
shared early environment, but also genetic dominance. A first limitation is whether 
we can distinguish sibship effects explaining early shared environment from domi-
nance variance. Sophisticated programmes such as SOLAR cannot make that distinc-
tion. This imposes serious limitations for the interpretations of the findings on body 
composition, which can for a large part be determined by early childhood nutrition 
and exercise. Although the sibship effect seen may most likely denote environmental 
effects, we cannot exclude dominance variance. 
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Another issue is the question of adjustment of the variables under study. We chose 
to adjust only for shared determinants with a strong impact on the outcome. We did 
not adjust for factors such as smoking, which may have a strong environmental back-
ground but may be partly under genetic control. Theoretically, the genetic correlation 
between depression and lipids and depression and socioeconomic status may be 
explained by a genetic correlation of smoking. We did not explore this further in the 
present study. In our analysis we adjusted for the fact that there is an increased level 
of distant consanguinity in an isolated population, which may inflate heritability. We 
did not adjust for other population genetic features such as assortative mating.  
Main Findings
Candidate Genes 
Association Studies
We investigated two polymorphisms in two genes involved in the renin angiotensin 
system (RAS). We studied the ACE I/D polymorphism in relation to MDD in the 
Rotterdam Study, and the AGT M235T polymorphism in relation to symptoms of 
depression in the Rotterdam Study and the ERF Study. We found no association 
between the ACE I/D polymorphism and MDD, but did find an association between 
the AGT M235T polymorphism and symptoms of depression in both the Rotterdam 
and ERF Studies. 
 The association of the AGT gene with symptoms of depression may be explained 
by the relationship between the RAS and the hypothalamic pituitary adrenal (HPA) 
axis. RAS directly modulates the HPA axis by stimulating corticotrophin hormones.11,12 
The presence of the T allele of the AGT gene increases the angiotensinogen level,13 
which in turn could enhance the HPA feedback and lead to symptoms of depression. 
In depressed patients there has been a consistent finding suggesting that hyperac-
tivity of the HPA axis increases both corticotrophin releasing hormone (CHR) and 
adrenocotropic hormone (ACTH). This feedback leads to higher levels of cortisol and 
aldosterone,14 which are typically seen in patients with depression.15
 We found the strongest association between AGT M235T and symptoms of de-
pression in men. This may raise questions about a different role of the AGT gene 
in men and women. Given that in both populations women had higher depression 
scores than men, it can be argued that other causal factors outweigh the role of AGT 
in women and mask an eventual effect of the gene in this subgroup. Alternatively, 
there is some earlier evidence that the RAS may have different roles in the etiology of 
depression for men and women. For example, aldosterone and renin plasma concen-
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trations, which are hormones that are part of the renin-angiotensin-aldosterone sys-
tem, were increased in depressed men,16,17 but not in depressed women.18 Another 
study found an increased frequency of panic disorders among men carrying the AGT 
T allele compared to non-carriers, but this association was not found in women.19 
However, it is important to note that we have to be careful with the interpretation 
of subgroup analysis. A recent review of Patsopoulos et al. showed that differences 
in effects across gender often did not replicate, nor was there an a priori reason to 
study differential effects.20 Our finding therefore awaits replication.
 Contrary to our expectations, we found no association between the ACE gene 
and MDD, but we cannot completely rule out that the gene is not involved in depres-
sion since we have studied only one polymorphism. Recently, three studies reported 
statistically significant associations for two other polymorphisms in the ACE gene 
(rs4291, rs4295) with MDD.21,22 One of these studies included more than 1200 indi-
viduals in their study.22 Because we only investigated one polymorphism, we cannot 
exclude that other polymorphisms in the ACE gene are associated.
Meta-analysis
Our meta-analyses clearly showed that the number of genetic association studies 
in MDD is still very limited. Only 22 polymorphisms (6%) out of the 393 polymor-
phisms studied were investigated in at least three studies, but even in these, the total 
number of cases and controls was often not large enough to detect even a moderate 
association (OR ~1.2-1.5). Furthermore, most genes were investigated for only one 
polymorphism in the gene. Even if this single polymorphism appears not to be as-
sociated, there may still be other variants in the gene that are associated to MDD. It 
is evident that more research is needed.
 By reviewing and performing meta-analyses for all MDD case-control genetic 
association studies (Chapter 2), we found statistically significant associations for six 
polymorphisms in the following genes: apolipoprotein E (APOE), guanine nucleotide-
binding protein (GNB3), methylene-tetrahydrofolate reductase (MTHFR), serotonin 
transporter (SLC6A4), dopamine transporter (SLC6A3) and the dopamine receptor D4 
(DRD4).
 The SLC6A4 gene plays a role in the serotoninergic system. Serotonin has been 
the main focus in the research of depression.23 The hypothesis that this neurotrans-
mitter is involved in the etiology of depression derives retrospectively from pharma-
cological experience. Serotonin has been the target of treatment of depression for 
the last fifty years.23 The effect of the SLC6A4 gene was however very small. In fact, 
it was the gene with the lowest odds ratio (OR in alleles = 1.11 compared to 0.51, 
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1.20, 1.38, 1.73, 2.06 for the APOE ρ2, MTHFR 677T, GNB3 825T DRD4 48bp and 
SLC6A3).
 The effect of the SLC6A3 is also of interest, as it is involved in dopamine metabo-
lism. Depression is seen in Parkinson’s disease, one of the most common dopamine 
related disorders. Of interest is also the association we found in our meta-analyses 
that APOE, GNB3 and MTHFR are associated to MDD. Each of these genes has also 
been implicated in vascular disease. These associations are of interest in light of the 
co-occurrence of depression and symptoms of depression with vascular pathology 
(see next paragraph). 
Shared etiological pathways between depression and other traits
To guide and support genetic association studies, we investigated the role of genetic 
predisposition in the co-occurrence of symptoms of depression with socioeconomic 
status, cardiovascular risk factors and body composition. The rationale behind this 
research is to identify overlapping etiological pathways. Genes involved in these 
pathways can be studied as candidate genes in relation to depression. The following 
vascular risk factors were investigated: blood pressure, glucose levels, lipid levels 
and body composition. In our research, we found a genetic association between 
symptoms of depression and lipid parameters, and between symptoms of depression 
and socioeconomic status. 
 The finding that there is a genetic association between lipids and symptoms of 
depression in our population is in line with our finding that the APOE gene is as-
sociated with MDD in the meta-analysis. It is interesting to see that the APOE was 
found to be the most strongly associated gene to depression in terms of the OR in our 
meta-analysis. The OR of 0.51 implies an almost 2-fold reduction in MDD risk for 
carriers of the ε2 allele compared to the ε3 allele. Our finding is in line with earlier 
reviews concluding that genes in the phospholipids metabolism are of interest in 
relation to depression.24,25 A recent paper listed more than 100 candidate genes for 
proteins involved in the metabolism of phospholipids and fatty acids that could be 
associated to psychiatric disease.24 
 In recent years, there is increasing interest in the hypothesis that depression and 
cardiovascular risk factors may share common genetic pathways.26-28 The GNB3 
gene, which codes for an important signal traducing component of the cell mem-
brane, has been found to be associated to hypertension,29 and to depression in our 
meta-analysis (Chapter 2). The MTHFR gene, which is implicated in folate metabo-
lism, was found to yield a threefold increase in risk for premature cardiovascular 
disease,30 and a meta-analysis showed that individuals with the TT genotype have 
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a significantly higher risk of coronary heart disease.31 We found a significant as-
sociation of the MTHFR gene to MDD in our meta-analysis. In our analyses on the 
co-occurrence of symptoms of depression and cardiovascular risk factors, we only 
found a genetic association between symptoms of depression and lipid parameters, 
and could not confirm the results of the only previous study on this, which found a 
genetic association of depression with hypertension and cardiovascular disease.32
 In addition to the genetic correlation between symptoms of depression and lipid 
variables, we also found an association between symptoms of depression and socio-
economic status. Socioeconomic status is often viewed of as a purely environmental 
factor. However, our study showed that the heritability of socioeconomic status 
was even higher than that of symptoms of depression. The heritability estimate in 
our study was in line with previous studies that reported heritability estimates for 
socioeconomic status ranging from 0.30 to 0.50.33-36 Several studies have studied 
genetic polymorphisms in relation to socioeconomic status.37,38 In line with this find-
ing of genetic correlation and with the results of our meta-analysis, which found an 
association between MDD and APOE, an association between the APOE gene and 
socioeconomic status has been reported.38 It remains to be determined whether this 
finding is replicated by other studies.
Suggestions for future research 
Even though association studies in relation to depression have been performed since 
thirty years ago,39 our meta-analyses clearly showed that the number of genetic as-
sociations studies of MDD is still limited, and that only very few genetic variants have 
been studied. Clearly many more studies are needed. To date, very few candidate 
gene studies on MDD have targeted lipids. Candidate gene studies seem an outdated 
approach with the availability of new methods such as genome wide association 
studies, but these still need replication studies in candidate regions.
 The recent successes of the genome wide association studies have overshadowed 
the candidate gene studies that have been less successful. However, the key feature 
of the success of genome wide association studies has been that findings have been 
replicated by 3 or more other studies before publication. Such rigid, self-imposed 
criteria have never been used for candidate gene studies. 
 Genetic association studies now enter a new era of genome wide association 
studies. After 30 years of research using traditional association studies that investi-
gated a few polymorphisms in a single study, this approach enables the screening 
of hundreds of thousands for association simultaneously. Genome wide association 
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will be used more often, especially as ongoing technical developments allow for 
easy and relatively low-cost genotyping, which can now rapidly test 500,000 to 
1,000,000 single nucleotide polymorphisms (SNPs) across the human genome.40 
This method enables us to localize common genetic variants with small effects in 
depression as well. 
 As with single gene association studies, it is expected that a lack of power will 
be a drawback for finding genes associated to depression. One of the solutions is 
collaboration between centers. Collaborative efforts in genome-wide association 
studies are performed by the Genetic Association Information Network (GAIN) 
consortium.41 A key issue will be to standardize studies a priori, to enable stratified 
analyses and interaction analyses in future meta-analyses. 
 Studies have shown that environmental factors as well as genetic factors play 
an important role in the etiology of depression. Caspi et al have stressed the role of 
gene-environment interaction,40 and showed that depression less likely occurs in the 
absence of specific environment or life events. Furthermore, there is interest in the 
role of dietary factors. Deficiencies of folate, vitamin B12, iron, zinc, omega-3 fatty 
acid, and selenium tend to be more common among depressed than non-depressed 
persons.42 Additionally, folate deficiency may reduce the response to antidepres-
sants.43 It would be interesting to study, in relation to depression, the effect of iron-
containing food on the MTHFR gene, and the effects of diet in relation to the APOE 
gene.
 Finally, there is increasing interest in pharmacogenetics. Several studies have 
addressed the question of how antidepressants react differently to people with dif-
ferent genetic variants. For example there is considerable progress showing a role of 
P450 genes in the response to antidepressants.44 Pharmacogenetic epidemiology of 
depression will be an important area of research.
 In conclusion, candidate gene and genome wide association approaches are 
useful in the identification of depression susceptibility genes. The most important 
avenue to follow will be to enlarge the ongoing studies in terms of number of patients 
included, and to include sufficiently sized replication studies. Also linkage studies 
may still yield valuable findings on major genes, but these studies will also require 
large series of relatives and sufficiently sized replication sets. 
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summary
The aim of this genetic epidemiological thesis was to study candidate genes that 
play a role in the etiology of depression, and to obtain new insights about biological 
pathways that may be involved in the etiology of depression. 
 The identification of novel susceptibility genes and of shared etiological pathways 
was conducted in two large-scale studies: the Rotterdam Study and the Erasmus 
Rucphen Family (ERF) Study. The Rotterdam Study is a population-based cohort 
study in the Netherlands of 7,983 men and women aged 55 years and older. Base-
line measurements were obtained between 1990 and 1993. All participants were 
subsequently examined in follow-up examination rounds every 2-3 years. Analyses 
were performed on data from individuals who participated in the fourth assessment 
of the study (n=3,550), which took place from 2002 to 2004. The ERF Study is a 
large-scale family-based study, which is part of the Genetic Research in Isolated 
Populations programmes. This programme investigates the genetic origin of complex 
genetic disorders and traits in a genetically isolated community in the Southwest of 
the Netherlands. Genealogical data of this community date back to the middle of the 
sixteenth century. All descendants from 20 couples living in the isolate from 1850 to 
1900 were ascertained and living descendants of 18 years and older were invited to 
participate. Data were collected from 2002 to 2005.
 The work presented in this thesis focuses for the largest part on symptoms of 
depression. These were assessed using the Center for Epidemiologic Studies Depres-
sion Scale (CES-D), and the depression subscale of the Hospital Anxiety Depression 
Scale (HADS-D). Both scales are valid and reliable self-report measures of symptoms 
of depression. The CES-D consists of 20 items with total scores ranging from 0 to 
60, and the HADS-D of 7 items with scores ranging from 0 to 21. Higher scores 
indicate more symptoms of depression. In addition, we investigated major depressive 
disorder (MDD), which was defined following standard diagnostic criteria according 
to the manual of mental disorders (DSM-IV) or the International Classification of 
Diseases (ICD-10). 
 The thesis starts with a review of all genetic case-control association studies 
on MDD published before June 2007 (Chapter 2). This review included all case-
control studies that compared adults diagnosed with standard diagnostic criteria for 
MDD to controls from the general population. Studies were excluded if (1) cases 
were selected by questionnaires assessing symptoms of depression, (2) the study 
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population included bipolar patients, (3) the distribution of genotypes in the control 
population was not in Hardy-Weinberg Equilibrium, or (4) if the data were re-used in 
a larger study on the same polymorphism. We performed meta-analyses for genetic 
polymorphisms that had been investigated in at least three studies. The 183 papers 
that met our criteria addressed 393 polymorphisms in 102 genes. Twenty-two poly-
morphisms (6%) in 20 genes were investigated in at least three studies. Our meta-
analyses in Chapter 2 showed statistically significant evidence for the following MDD 
susceptibility polymorphisms: APOE ε2 (OR, 0.51), GNB3 825T (OR, 1.38), MTHFR 
677T (OR, 1.20), SLC6A4 44bp Ins/Del S (OR, 1.11) and the SLC6A3 40bpVNTR 9/10 
genotype (OR, 2.06). In Chapter 3 we report an association between the DRD4 2 al-
lele 48bp (OR, 1.73) and MDD. To date, there is evidence for six MDD susceptibility 
genes: APOE, DRD4, GNB3, MTHFR, SLC6A3 and SLC6A4. 
 We further investigated two polymorphisms in the renin angiotensin system (RAS), 
the ACE I/D polymorphism in relation to MDD in the Rotterdam Study, and the AGT 
M235T polymorphism in relation to symptoms of depression in both the Rotterdam 
Study as well as in the ERF Study. We found no association between the ACE I/D 
polymorphism and MDD in our study nor in a meta-analysis (Chapter 4), but an 
association between the AGT M235T polymorphism and symptoms of depression 
was found in both the Rotterdam and ERF Studies, with the strongest association in 
men (Chapter 5).
 Chapters 6 to 8 focus on co-morbidity and aim at the identification of biological 
pathways that may be involved in the etiology of depression. For this purpose, the 
roles of shared genetic and shared environmental factors in the co-occurrence of 
symptoms of depression and other variables were quantified by genetic (ρG) and 
environmental (ρE) correlations. Genetic and environmental correlations range from 
-1 to +1 and express to what extent two traits are influenced by the same genes 
(ρG), and the same environmental factors (ρE), respectively. Analyses were adjusted 
for age, sex, use of antidepressant medication, degree of consanguinity and sibship 
effects. In Chapter 6 the role of shared genetic factors in the co-occurrence of symp-
toms of depression and socioeconomic status was investigated. Significant genetic 
correlations were found between education and symptoms of depression (CES-D: 
ρG=-0.65, p<0.001; HADS-D: ρG=-0.50; p<0.001), suggesting that shared genetic 
factors play a role in the clustering of depression among individuals with lower 
socioeconomic status. Chapter 7 describes the role of shared genetic factors in the 
co-occurrence of symptoms of depression and cardiovascular risk factors such as 
blood pressure, glucose levels and lipid parameters. Our study showed evidence for 
shared genetic factors contributing to the co-occurrence of symptoms of depression 
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and lipid parameters. Significant genetic correlations were found between CES-D 
scores and total plasma cholesterol (ρG=0.30), LDL (ρG=0.31) and total cholesterol/
HDL ratios (ρG=0.25). Significant genetic correlations were also found for HADS-D 
scores with total cholesterol/HDL ratios (ρG=0.27). In Chapter 8 we report that 
there is no evidence that the co-occurrence of symptoms of depression and body 
composition result from the same genetic factors. 
 In Chapter 9 the results are interpreted from a genetic epidemiological perspec-
tive and suggestions for future research are discussed. The major conclusions of 
the thesis are that the number of genetic association studies of MDD is still limited, 
as only 393 genetic variants have been studied and that more genetic association 
studies are needed. Our data suggests that there is a genetic predisposition in the 
co-occurrence of symptoms of depression with both socioeconomic status and lipid 
parameters. This last finding may guide and support future genetic association stud-
ies. 
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Het doel van dit genetisch-epidemiologisch proefschrift is het bestuderen van kan-
didaatgenen die een rol spelen in de etiologie van depressie, alsmede het verkrijgen 
van nieuwe inzichten in de biologische trajecten die betrokken kunnen zijn bij de 
etiologie van depressie. 
 De identificatie van nieuwe gevoeligheidsgenen en van gedeelde etiologische 
trajecten werd uitgevoerd in twee grootschalige studies: de Rotterdam Studie en de 
Erasmus Rucphen Familie (ERF) Studie. De Rotterdam Studie is een population-based 
cohort studie in Nederland van 7.983 mannen en vrouwen van 55 jaar en ouder. De 
eerste gegevens werden verzameld tussen 1990 en 1993. Alle deelnemers werden 
vervolgens elke 2 tot 3 jaar opnieuw onderzocht. Analyses werden uitgevoerd op de 
gegevens van personen die deelnamen aan de vierde evaluatieronde van het onder-
zoek (n=3.550), dat plaatsvond van 2002 tot 2004. De ERF Studie is een grootschalige 
familiegebaseerde studie, die deel uitmaakt van het Genetic Research in Isolated 
Populations programma. Dit programma onderzoekt de genetische oorsprong van 
complexe genetische aandoeningen en eigenschappen in een genetisch geïsoleerde 
gemeenschap in het zuidwesten van Nederland. Genealogische gegevens van deze 
gemeenschap dateren uit het midden van de zestiende eeuw. Alle nakomelingen van 
20 echtparen die in het isolaat leefden van 1850 tot 1900 werden opgespoord en 
levende nakomelingen van 18 jaar en ouder werden uitgenodigd om deel te nemen 
aan het onderzoek. Gegevens zijn verzameld van 2002 tot 2005. 
 Het werk beschreven in dit proefschrift richt zich voor het grootste deel op 
symptomen van depressie. Deze werden bepaald aan de hand van de Center for 
Epidemiologic Studies Depression schaal (CES-D), en de depressie subschaal van 
de Hospital Anxiety Depression Scale (HADS-D). Beide schalen zijn valide en be-
trouwbare zelfgerapporteerde metingen van symptomen van depressie. De CES-D 
bestaat uit 20 items met totale scores variërend van 0 tot 60 en de HADS-D uit 
7 items met scores variërend van 0 tot 21. Hogere scores duiden op meer symp-
tomen van depressie. Daarnaast onderzochten we depressieve stoornis (MDD), 
die werd gedefiniëerd door middel van standaard diagnostische criteria volgens de 
handleiding psychische stoornissen (DSM-IV) of de International Classification of 
Diseases (ICD-10). 
 Het proefschrift begint met een overzicht van alle genetische patiënt-controle 
associatie studies naar MDD gepubliceerd vóór juni 2007 (Hoofdstuk 2). Dit over-
zicht omvatte alle patiënt-controle studies die volwassenen gediagnosticeerd met 
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standaard diagnostische criteria voor MDD (de cases) vergeleek met controles uit 
de algemene bevolking. Studies werden uitgesloten als (1) cases werden geselect-
eerd door vragenlijsten die symptomen van depressie beoordeelden, (2) de studie 
bipolaire patiënten omvatte, (3) de genotypenverdeling van de controle groep niet in 
Hardy-Weinberg evenwicht was, of (4) als de gegevens opnieuw werden gebruikt in 
een grotere studie van hetzelfde polymorfisme. We voerden meta-analyses uit voor 
genetische polymorfismen die waren onderzocht in ten minste drie studies. De 183 
artikelen die aan onze criteria voldeden onderzochten in totaal 393 polymorfismen 
in 102 genen. Tweeëntwintig polymorfismen (6%) in 20 genen werden onderzocht 
in ten minste drie studies. Onze meta-analyses in Hoofdstuk 2 lieten statistisch sig-
nificant bewijs zien voor de volgende polymorfismen: APOE ε2 (OR, 0.51), GNB3 
825T (OR, 1.38), MTHFR 677T (OR, 1.20), SLC6A4 44bp Ins/Del S (OR, 1,11) en 
het SLC6A3 40bpVNTR 9/10 genotype (OR, 2.06). In Hoofdstuk 3 rapporteren we 
over een associatie tussen de DRD4 2-allel 48bp (1.73) en MDD. Tot op heden is er 
bewijs voor zes MDD gevoeligheidsgenen: APOE, DRD4, GNB3, MTHFR, SLC6A3 
en SLC6A4. 
 We onderzochten verder twee polymorfismen in het renine-angiotensine systeem 
(RAS): het ACE I/D polymorfisme in relatie tot MDD in de Rotterdam Studie en het 
AGT M235T polymorfisme in verband met de symptomen van depressie in zowel de 
Rotterdam Studie en de ERF Studie. We vonden geen associatie tussen het ACE I/D 
polymorfisme en MDD in onze studie noch in een meta-analyse (Hoofdstuk 4), maar 
een associatie tussen het AGT M235T polymorfisme en symptomen van depressie 
werd gevonden in zowel de Rotterdam Studie en de ERF Studie, met de sterkste 
associatie bij mannen (Hoofdstuk 5). 
 Hoofdstukken 6 tot en met 8 richten zich op co-morbiditeit en trachten biologis-
che trajecten die betrokken kunnen zijn bij de etiologie van depressie te identificeren. 
Voor dit doel werden de rollen van gedeelde genetische en omgevingsfactoren in 
het gezamenlijk optreden van de symptomen van depressie en andere variabelen 
gekwantificeerd door genetische (ρG) en omgevingscorrelaties (ρE). Genetische en 
omgevingscorrelaties variëren van -1 tot +1 en drukken uit in welke mate twee eigen-
schappen worden beïnvloed door respectievelijk dezelfde genen (ρG), en dezelfde 
omgevingsfactoren (ρE). Analyses werden gecorrigeerd voor leeftijd, geslacht, het 
gebruik van antidepressiva, de mate van bloedverwantschap en sibship effecten. 
In Hoofdstuk 6 wordt de rol van gedeelde genetische factoren in het gezamenlijk 
optreden van de symptomen van depressie en de sociaal-economische status onder-
zocht. Aanzienlijke genetische correlaties zijn gevonden tussen onderwijs en symp-
tomen van depressie (CES-D: ρG=-0,65, p<0,001; HADS-D: ρG=-0,50; p<0,001), 
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wat erop wijst dat gedeelde genetische factoren een rol spelen bij de clustering 
van depressie bij mensen met een lagere sociaal-economische status. Hoofdstuk 7 
beschrijft de rol van gedeelde genetische factoren in het gezamenlijk optreden van 
symptomen van depressie en cardiovasculaire risicofactoren zoals bloeddruk, glu-
cose niveaus en lipidenconcentratie. Onze studie draagt bewijs aan voor het bestaan 
van gedeelde genetische factoren die bijdragen aan het gezamenlijk optreden van 
depressieve symptomen en lipidenconcentratie. Aanzienlijke genetische correlaties 
werden gevonden tussen de CES-D scores en het totale plasma cholesterol (ρG=0,30), 
LDL (ρG=0,31) en totaal cholesterol / HDL ratios (ρG=0,25). Aanzienlijke genetische 
correlaties werden ook gevonden voor HADS-D scores met een totaal cholesterol / 
HDL ratio (ρG=0,27). In Hoofdstuk 8 melden wij dat er geen aanwijzingen zijn dat 
gezamenlijk optreden van de symptomen van depressie en lichaamssamenstelling 
het gevolg zijn van dezelfde genetische factoren. 
 In Hoofdstuk 9 worden de resultaten geïnterpreteerd vanuit een genetisch-epide-
miologisch perspectief en worden suggesties voor toekomstig onderzoek besproken. 
De belangrijkste conclusies van het proefschrift zijn dat het aantal genetische as-
sociatie studies van MDD nog steeds beperkt is, aangezien slechts 393 genetische 
varianten zijn onderzocht en dat er meer genetische associatie studies nodig zijn. 
Onze resultaten suggereren dat er sprake is van een genetische aanleg in het geza-
menlijk optreden van symptomen van depressie met zowel sociaal-economische 
status en lipidenconcentratie. Deze laatste conclusie kan richting en steun bieden bij 
toekomstige genetische associatie studies.
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resumen
El objetivo de esta tesis es identificar genes que desempeñan un papel en la etiología 
de la depresión, y obtener nuevos conocimientos acerca de las vías biológicas que 
pudieran estar implicadas en dicha etiología. 
 La identificación de nuevos genes de susceptibilidad a la depresión y de vías 
genéticamente compartidas entre depresión y otras variables, fueron realizadas den-
tro del Rotterdam Study y el Erasmus Rucphen Family Study (ERF); dos estudios de 
gran escala. El Rotterdam Study es un estudio de cohorte poblacional llevado a cabo 
en los Países Bajos. En él participaron 7.983 hombres y mujeres mayores de 55 años. 
Los primeros datos de referencia se recolectaron entre 1990 y 1993. Cada dos a tres 
años todos los participantes fueron reexaminados. Los análisis incluidos en esta tesis 
engloban información de la cuarta evaluación del estudio (n = 3.550), que tuvo lugar 
entre 2002 y 2004. El ERF Study investiga el origen de enfermedades complejamente 
genéticas en una comunidad genéticamente aislada en el suroeste de los Países 
Bajos. Datos genealógicos de esta comunidad se remontan a mediados del siglo XVI. 
Todos los descendientes mayores de 18 años procedentes de 20 parejas que vivieron 
en la población fueron invitados a participar. Los datos se recolectaron entre los 
años 2002 a 2005. 
 Para evaluar síntomas de depresión se utilizaron dos escalas: la Escala de 
Depresión del Centro de Estudios Epidemiológicos (CES-D) y la Sub-escala de 
Depresión de la Escala Hospitalaria de Ansiedad y Depresión (HADS-D). La escala 
CES-D consta de 20 preguntas que derivan en una puntuación del 0 a 60. La escala 
HADS-D incluye 7 preguntas que derivan un puntaje del 0 a 21. Los puntajes más 
altos indican un mayor grado de síntomas de depresión. El diagnóstico de depresión 
mayor se definió siguiendo los criterios del Manual Diagnóstico y Estadístico de 
los Trastornos Mentales de la Asociación Psiquiátrica Americana (DSM-IV por sus 
siglas en inglés) o la Clasificación Estadística Internacional de Enfermedades y Otros 
Problemas de Salud (CIE-10). 
 La tesis comienza con una revisión de todos los estudios de asociación genética 
sobre depresión mayor publicados antes de junio del 2007 (Capítulo 2). Incluimos 
estudios en los que los casos fueron de adultos diagnosticados con depresión mayor, 
y en los que los controles fueron escogidos en la población general. Los criterios de 
exclusión de publicaciones fueron los siguientes: (1) si los casos fueron selecciona-
dos por cuestionarios de evaluación de síntomas de la depresión, (2) si la población 
de estudio incluyó pacientes bipolares, (3) si la distribución de genotipos en los 
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controles no estaba en equilibrio Hardy-Weinberg, o (4) si los datos se repetían en 
otro estudio sobre el mismo polimorfismo. Se realizó un metaanálisis si al menos tres 
estudios investigaban el mismo polimorfismo genético. En total, 183 publicaciones 
cumplieron con los criterios de inclusión. En éstos, 393 polimorfismos en 102 genes 
fueron estudiados. Se valoraron con metaanálisis 22 polimorfismos (6%) en 20 genes. 
Se encontraron 5 polimorfismos genéticos de susceptibilidad a depresión mayor: 
APOE ε2 (OR 0,51), GNB3 825T (OR 1,38), MTHFR 677T (OR 1,20), SLC6A4 44bp 
Ins/Del S (OR 1,11) y el SLC6A3 40bpVNTR genotipo 9/10 (OR 2,06). En el Capítulo 
3 fue encontrada una asociación entre el alelo 2 del gen DRD4 48bp (OR 1,73) y 
depresión mayor. Nuestros metaanálisis reportan que hasta la fecha hay evidencia 
de que seis genes están asociados a depresión mayor: APOE, DRD4, GNB3, MTHFR, 
SLC6A3 y SLC6A4. 
 En los siguientes capítulos se investigaron dos polimorfismos en el sistema de 
renina angiotensina (RAS), el polimorfismo ACE I/D en relación a depresión mayor 
en el Rotterdam Study y el polimorfismo AGT M235T en relación a síntomas de 
depresión tanto en el Rotterdam Study así como en el ERF Study. No se encontró 
asociación entre el polimorfismo ACE I/D y depresión mayor ni en nuestra población 
ni en nuestro metaanálisis (Capítulo 4). Así mismo, sí se encontró una asociación 
entre el polimorfismo AGT M235T y síntomas de depresión en ambas poblaciones 
que estudiamos. Esta asociación se encontró presente en hombres (Capítulo 5). 
 Los capítulos 6 a 8 se centraron en obtener nuevos conocimientos acerca de las 
vías biológicas que pudieran estar implicadas en la etiología de la depresión. Con 
este fin hemos determinado si variables correlacionadas con depresión comparten 
una base genética con síntomas de esta enfermedad. Las correlaciones genéticas 
(ρG) y las ambientales (ρE) se reportaron. Éstas van desde -1 a +1 y expresan en 
qué medida dos rasgos están influenciados por los mismos genes (ρG) o por los 
mismos factores ambientales (ρE). Los análisis fueron ajustados por edad, sexo, me-
dicamentos para depresión, grado de consanguinidad y efecto de hermandad. En el 
Capítulo 6 hemos investigado la presencia de factores genéticos compartidos en la 
concurrencia de síntomas de depresión y educación. Se encontraron correlaciones 
genéticas significativas entre educación y síntomas de depresión (CES-D: ρG=-0,65, 
p<0,001; HADS-D: ρG=-0,50, p<0,001). Estos resultados sugieren que existen fac-
tores genéticos compartidos entre síntomas de depresión y estatus socioeconómico. 
En el Capítulo 7 hemos estudiado la existencia de factores genéticos compartidos 
entre síntomas de depresión y factores de riesgo cardiovascular. Las variables de 
riesgo cardiovascular incluidas fueron presión arterial, niveles de glucosa y parámet-
ros de lípidos. Se encontraron correlaciones genéticas significativas entre CES-D 
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y colesterol total en plasma (ρG=0,30), LDL (ρG=0.31) y la proporción colesterol 
total/HDL (ρG=0.25). Respecto a HADS-D se encontraron correlaciones genéticas 
significativas con la proporción colesterol total /HDL (ρG=0,27). En el Capítulo 8 
hemos reportado que no hay pruebas de que la concurrencia de los síntomas de la 
depresión y la obesidad tengan una base genética común.
 En el Capítulo 9 se han interpretado estos resultados desde una perspectiva de 
epidemiología genética; además, se ofrecen sugerencias para investigación futura. 
Las principales conclusiones de la tesis son que el número de estudios de asociación 
genética de depresión mayor son limitados, ya que sólo 393 variantes genéticas han 
sido estudiadas. Nuestros metaanálisis muestran evidencia de que hasta la fecha hay 
seis genes que están asociados a depresión mayor: APOE, DRD4, GNB3, MTHFR, 
SLC6A3 y SLC6A4. Las correlaciones genéticas mostradas sugieren que existe una 
predisposición genética en la concurrencia de síntomas de depresión tanto con 
el nivel socioeconómico, como con los parámetros lipídicos. Este último hallazgo 
pudiera guiar y respaldar estudios de asociación genética en el futuro.
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